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ContractilityCardiomyocytes from human pluripotent stem cells (hPSCs-CMs) could revolutionise biomedicine. Global
burden of heart failure will soon reach USD $90bn, while unexpected cardiotoxicity underlies 28% of drug
withdrawals. Advances in hPSC isolation, Cas9/CRISPR genome engineering and hPSC-CM differentiation have
improved patient care, progressed drugs to clinic and opened a new era in safety pharmacology. Nevertheless,
predictive cardiotoxicity using hPSC-CMs contrasts from failure to almost total success. Since this likely relates
to cell immaturity, efforts are underway to use biochemical and biophysical cues to improve many of the ~30
structural and functional properties of hPSC-CMs towards those seen in adult CMs. Other developments needed
for widespread hPSC-CM utility include subtype speciﬁcation, cost reduction of large scale differentiation and
elimination of the phenotyping bottleneck. This review will consider these factors in the evolution of hPSC-CM
technologies, as well as their integration into high content industrial platforms that assess structure, mitochon-
drial function, electrophysiology, calcium transients and contractility. This article is part of a Special Issue
entitled: Cardiomyocyte Biology: Integration of Developmental and Environmental Cues in the Heart edited by
Marcus Schaub and Hughes Abriel.
© 2015 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Human embryonic stem cells (hESCs) were ﬁrst isolated from blas-
tocyst stage embryos in 1998 [1], with later demonstration of human
induced pluripotent stem cell (hiPSC) reprogramming from somatic
cells by just four genetic factors [2]. The ability to culture these human
pluripotent stem cell (hPSC) populations long-term and yet induce
their differentiation into a wide variety of cell types potentially offers
a new era in biomedicine, particularly for understanding human devel-
opment, drug screening, disease modelling and cell therapy to replace
lost or damaged tissues.
The socioeconomic drivers for development of new technologies
to address these biomedical areas are strong. The UK Departmentyocyte Biology: Integration of
edited by Marcus Schaub and
enning).
. This is an open access article underfor Innovation, Research & Skills [3] concluded that 80% of healthcare
costs go towards treating the late stages of illnesses, which in the
future could be cured early or better managed by regenerative
medicine and cell replacement approaches. The global burden of
heart failure is currently USD $45bn, with a forecast of USD $90bn
by 2030. These sobering statistics have prompted more than a decade
of autologous stem cell trials to treat heart failure, predominantly
using cell populations derived the bone marrow. However, the efﬁca-
cy of such treatments has been called into doubt with the realisation
that only trials containing ﬂaws (e.g. design or reporting errors)
showed positive outcomes, while error-free trials showed no beneﬁt
[4].
The pharmaceutical industry faces equivalent challenges. Average
drug development duration is 10–15 years with costs as high as USD
$11bn [5]. Between 1980 and 2009, ~1 in 7 licenced drugs deemed efﬁca-
cious in Phase III trials had to be withdrawn from the market. The main
reasons included unanticipated side-effects, such as cardiotoxicity, hepa-
totoxicity and gastro-intestinal issues [6]. Unexpected cardiotoxicity wasthe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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effects can damage the structural integrity and survival of cardiomyocytes
(CMs), as is the case with the anti-inﬂammatory drug, Vioxx [8], and
many anti-cancer drugs, such as doxorubicin [9]. Beat regularity and du-
ration (QT prolongation or shortening) can also be affected, potentially
leading to polymorphic ventricular tachyarrhythmia, seizures and sudden
death. In 2010 thiswas the reason for theUS Food andDrug Administra-
tion (FDA) requesting withdrawal of propoxyphene, an opioid pain re-
lievermarketed by Xanodyne Pharmaceuticals [10], and of sibutramine,
a weight loss agent marketed by Abbott Laboratories [11]. In the worst
cases, adverse side effects lead to fatalities, as was the case with the
serotonin agonist, cisparide, which caused 125 deaths before its use
ceased [12].
1.1. Current safety assessment platforms are suboptimal
Underlying poor predictivity of cardiotoxicity are suboptimal safety
assessment platforms. While human primary CMs would be the
in vitro model of choice, their large-scale use is hindered by limited
availability, poor consistency, almost non-existent proliferation and
de-differentiation in culture [13]. Consequently, various other models
are used. Provisional safety screens often involve aneuploid tumour cell
lines (e.g. CHO or HEK cells) genetically engineered to over-express an
ion channel of choice. While high throughput, these cells do not replicate
the complexity of the working CM and can lead to false negatives or pos-
itive. Thus, themulti-channel blocking drug, verapamil, is considered safe
and “QT-neutral” on account of dual blocking of potassium IKr and calcium
Ica,L channels but can be ﬂagged as potentially harmful in the single ion
channel assays [14]. Ex vivo systems, such as ventricular wedge prepara-
tions [15] and Purkinje ﬁbres [16], have been extensively used in physio-
logical and pharmacological studies, but low-throughput and inter-
species differences are limitations.
Species differences are particularly highlighted in the mouse [13].
While this species beneﬁts from genetic tractability via gene targeting,
the beat rate of the mouse heart is ~10 times faster than human
(500 bpm vs 60 bpm) and has an electrocardiogram duration 5–10
times shorter (450 ms vs 50-100ms). Increases in heart rate are associ-
ated with increased force of contraction in humans but decreased force
inmice [17].Whereas repolarisation of themouse CMs is driven primar-
ily by Ito, IK,slow1, IK,slow2, ISS ion channels, this role is achieved by the po-
tassium channels, IKr and IKr in human cells [18]. There are species
differences in the role of the regulatory molecule, phospholamban,
while expression of structural genes also varies. In humans, expression
of alpha and beta myosin heavy chains (α−/β-MHC) locates to the
atria and ventricles, respectively, but in the mouse αMHC is expressed
in both locations. There are also differences in developmental progres-
sion and location of themyosin light chains,MLC2a andMLC2v. The sur-
face marker, SIRPA, is expressed on human but not mouse CMs. Such
differences mean that mice are at least 10× more tolerant to 37% of
drugs than humans. Issues extend to rats and dogs, which tolerate 4.5-
to 100-fold the concentration of various chemotherapeutic agents
than humans (e.g. ThioTEPA, Myleran, Actinomycin-D, Mitomycin C,
Mithramycin, Fludarabine) [19].
Reducing drug attrition by 5% in Phase 1 clinical development could
reduce drug development costs by 5.5–7.1% [20] equating to savings of
about USD $100m. Thus, there has been considerable effort invested in
ﬁnding additional tools for safety assessment, which include hPSC-CMs.
1.2. Evolution of hPSC-CM differentiation
With the issues above, it was a certain degree of excitement that, in
2000, Joseph Itskovitz-Eldor's team demonstrated contracting struc-
tures containing CMs could be produced by spontaneous differentiation
of hESCs via three-dimensional embryoid bodies [21]. Subsequent re-
search has shown that CMs derived from both hESC and hiPSC display
many of the structural and functional features associated with heartcells (for review [13]). This promoted development and evaluation
of three general strategies to improve differentiation efﬁciency: 3-
dimensional aggregates known as embryoid bodies; co-cultures with
an inducer END-2 cell line; 2-dimensional monolayers (reviewed in
[22]). Initially, these approaches produced purities of b50% hPSC-CMs
and additional enrichmentwas needed to go beyond 90% purity. Genet-
ic selection strategies were developed ﬁrst. These employed random in-
tegration into the hESC genome of expression cassettes that coupled
cardiac speciﬁc promoters (e.g.MYH6 encoding αMHC) with puromy-
cin antibiotic resistance [23]. Gene targeting allowed reﬁnement by pre-
cise positioning of the NeoR gene downstream of MHY6 [24]; this
approach is still used for commercial production by Cellular Dynamics
International (CDI) since it enables selection of CMs at mass scale.
Purity of hPSC-CMs has also been improved by FACS sorting for cells
expressing markers associated with cardiac progenitors (CD15; SSEA1
[25]) or CMs (e.g. VCAM1, SIRPA [26]) and for cells incubated with mo-
lecular beacons targeting mRNAs that encode cardiac troponin and
MHCs [27]. Sorting has been achieved following staining with themito-
chondrial dye, TMRM, on the basis that highly metabolic CMs will have
the highest numbers of mitochondria and hence have high level of ﬂuo-
rescence [28]. However, these approaches are neither economically nor
practically viable for large scale production of hPSC-CMs due to slow
sort speeds (maximum 70,000 cells/s) and poor survival after coupling
dissociation with FACS. This approach would require over 2 weeks to
harvest 10 billion hPSC-CMs, which is the number estimated from pri-
mate studies to be required for transplantation to restore function into
the infarcted human heart of a single patient [29].
In an effort to develop mass enrichment strategies that do not re-
quire bespoke genetic modiﬁcation approaches for each hPSC line,
Tohyama et al. [30] exploited the metabolic differences between CMs
and the contaminating (predominantly) ﬁbroblast populations. While
ﬁbroblasts rely on glucose-based metabolism, hPSC-CMs can utilise
both lactate and glucose. Purities of 99% were achieved by incubating
hPSC-CMs in medium that contained 4 mM lactate but lacked glucose
and this approach is becoming popular. Microﬂuidic approaches has
also been used to separate cells on the basis of size [31] or electrophys-
iological signals [32] but the considerable heterogeneity in differentiat-
ed hPSC-CM cultures means these physical approaches will require
further validation.
While these enrichment approaches have been useful as an interim
measure, efforts to develop differentiation protocols that produce
hPSC-CMs at high purity have reached fruition in the last 3–4 years.
Monolayer protocols (see Table 1) are popular due to ease of handling
and large scale production of ~7 billion hPSC-CMs [29]. Clues on how
cardiogenesis proceeds in vivo in a coordinated, stepwise manner
have been derived from various model species. In mammals, progres-
sion from gastrulation, through formation of the primitive streak and
epiblast towards development of the linear heart tube shows the impor-
tance of signalling via pathways involving transforming growth factor
beta (TGF-β; including bone morphogenetic protein [BMP] and Activin
A), basic ﬁbroblast growth factor (bFGF; FGF2) and Wingless (WNT).
Translating these developmental signals to hPSCs in vitro has been em-
pirical and iterative but has deﬁned the concentrations and timings of
growth factors and/or small molecules that activate or inhibit relevant
cardiogenic pathways (Table 1). Commercial media, such as mTeSR
and Essential 8 (E8), increase reproducibility of culture and differentia-
tion by eliminating need for steps involving serum, serum replacements
or conditioned medium. Relative to recombinant growth factors, use of
chemically synthesised small molecules reduces variability and cost.
Thus, monolayer cardiogenic protocols now routinely employ deﬁned
medium with the GSK3β inhibitor, CHIR99021, during the ﬁrst 1–
3 days of differentiation process, followed by inhibition of WNT using
IWR1, IWR4, C59 or XAV939 (Table 1).
Although efﬁciencies of N80% are now regularly reported for hPSC-
CM differentiation (Table 1), unpublished anecdotal evidence suggests
reproducibility and robustness of protocols needs to be improved so
Table 1
Methods for monolayer differentiation of hPSC-CMs. Abbreviations: MEF-CM, mouse embryonic ﬁbroblast-conditioned medium; E8, Essential 8 medium; Reprog, Reprogramming method; N/A, not applicable; Retro, retrovirus; Lenti, lentivirus;
Epi, Epsiomal; AA, activin A; V, ventricular; A, atrial; N, nodal (or pacemaker).
Time
line
hPSC line(s) Medium Substrate Reprog Differentiation procedure Efficiency Subtypes Ref
2007 hESC: H7 MEF–CM Matrigel N/A 30% V,A 198
2011
hESC: H7 MEF–CM Matrigel N/A 70% V,A,N 199
hESC: KhES1; hiPSC lines:
201B6, 201B7, 253G1,
253G4
MEF–CM Matrigel Retro; Lenti 60% V,A 200
Engineered hESC: H3, M1 MEF–CM Matrigel None 40% V,A 78
2012 hESC: H9, H13, H14hiPSC:IMR90C4 mTESR1 Matrigel Epi; Lenti 85% V,A 201
2013 hESC: H1, H9hiPSC: hAFDC–iPS–36 mTESR1 Matrigel Retro 80% V,A 202
2014
hESC: H7, H9
hiPSC: 58FSDNC3,
64FSDNC1
E8 Matrigel, Laminin,Vitronectin Sendai 90% V,A 174
2015 hPSCs: Line N/S. E8, mTESR,MEF–CM Matrigel N/S 80% V,A 203
AA BMP4
RPMI/B27
BMP4;
FGF2 AA Noggin DKK1+Rai/RA DKK1
RPMI/B27
AA BMP4 + FGF2 DKK1
RPMI/B27 (–insulin) RPMI/B27
CHIR IWP2; IWP4
RPMI/B27 (–insulin) RPMI/B27
AA; BMP4; FGF2;
VEGFA; SCF
LI–APEL LI–PEL
CHIR; BMP4;
Ascorbate BMP4; IWR1
CIM RPMI/B27 (–insulin) RPMI/B27
CHIR WNT–C59
CDM3
BMP4; AA; CHIR XAV939
Cardiac differentiation medium
D0 D1 D2 D3 D4 D5 D6 D7 D8 D9 D10 D11 D12
1730
C.D
enning
etal./Biochim
ica
etBiophysica
A
cta
1863
(2016)
1728–1748
1731C. Denning et al. / Biochimica et Biophysica Acta 1863 (2016) 1728–1748there is greater consistency between lines and laboratories. Also, proto-
cols yield a mixed population of CM subtypes, including ventricular-,
atrial- and pacemaker-like cells. Cultures containing a single subtype
are preferred; for example, ventricular cells are needed to evaluate
drugs that have Torsades de Pointe liabilities or for transplantation
after myocardial infarction. In this regard, there have been recent excit-
ing developments. Birket and colleagues [33] combined a complex but
elegant double transgenic approach, wherein an NKX2.5-GFP targeted
hESC line was further transfected with an inducible MYC expression
construct. In the presence of insulin-like growth factor-1 (IGF-1) and a
hedgehog pathway agonist, cardiovascular progenitor cells could be iso-
lated and proliferated for over 40 population doublings. Moreover,
modulating exogenous BMP, FGF, WNT and RA signalling led to multi-
lineage differentiation, as well as directed speciﬁcation to pacemaker
and ventricular cells. This report was remarkable because it not only
showed long-term proliferation of hPSC-derived cardiac progenitors
(in 11 other reports using mouse and human PSCs, maximum expansion
was 4-fold [34]), but it was the ﬁrst robust demonstration of subtype
speciﬁcation. In an alternative approach, modulation of retinoic acid sig-
nalling during hESC differentiation was used to generate atrial- and
ventricular-like CMs. These CM subtypes were used to show that the
multi-ion channel blocker, vernakalant, and Kv1.5 blocker, XEN-D0101,
caused a reduction in early repolarization only in the atrial cells [35], pro-
viding a novel preclinical test platform for these drug classes.
1.3. Genotypes are now readily captured using hiPSC reprogramming
Improvements in CM differentiation have been paralleled by
advances in hiPSC production methods. The original landmark papers
by Shinya Yamanaka's teamand the reports thereafter described low ef-
ﬁciency (b0.1%) production of hiPSCs via integrating retroviruses [2]
in undeﬁned medium on mitotically-inactivated mouse embryonic
ﬁbroblasts. Technologies have evolved so that academic and commer-
cial labs now produce hiPSC lines at efﬁciencies of ~4.4% using non-
integrating approaches in deﬁned medium on recombinant matrices
[36] Indeed, large scale banking schemes includingHuman Induced Plu-
ripotent Stem Cells Initiative (HIPSCI), StemBANCC/IMI, California Insti-
tute for RegenerativeMedicine and NewYork StemCell Foundationwill
create hiPSC lines from 7000 normal or diseased skin biopsy donors
using Sendai-virus, episomes or mRNA with a combination of SOX2,
c-MYC, OCT4, KLF4 and/or LIN28 [37]. Nevertheless, each integration-
free method has pros and cons and there is not yet consensus on
which reprogramming method is best. Episomal plasmids have lower
reprogramming efﬁciencies and the potential for residual plasmid inte-
gration; Sendai-virus require higher biosafety containment levels and
are relatively costly; mRNA reprogramming is labour intensive, requir-
ing repeated (daily) transduction and costly Pluriton medium. In
addition, there are licencing cost implications and restrictions to be con-
sidered for commercial use for Sendai-virus and mRNA approaches.
1.4. hPSC-CMs are becoming valuable for in vitro and in vivo biomedical
application
The relative ease of efﬁcient reprogramming and directed cardio-
genesis has accelerated progress towards biomedical application. This is
helped by hiPSCs largely eliminating ethical or legal restrictions that
prohibited use of hESCs in many companies and countries. For predictive
cardiotoxicity, many reports show hPSC-CMs are effective in safety
screening. In the 13 years from 2000 to 2013, pharmacological responses
of hPSC-CMs to only 60 different compounds had been demonstrated
[13]. Thesenumbers arenowbeing exceededby single studies; one report
assessed impact of 131 compounds of hPSC-CM function [38].
Accuracy of the assays is also improving and gaining interest from
the pharmaceutical industry. Using hPSC-CMs, AstraZeneca showed
70% speciﬁcity and 87% sensitivity for a 51 compound screen [39],
while a study commissioned by J&J recorded an accuracy of 90% followingblind testing of electrical toxicity in 20 compounds [40]. Work from
GlaxoSmithKline cross-compared pharmacological responses of hPSC-
CMs and animal models, concluding that the human cells offered a reli-
able and cost-effective surrogate to preclinical in vitro testing [41]. Direct
comparison between CMs isolated from hPSCs or dog and rabbit hearts
showed the human cells more accurately predicted moxiﬂoxacin-
induced cardiotoxicity [42]. Studies have extended to screening antivirals
as a treatment for B3-strain of coxsackievirus, a major causative agent for
viralmyocarditis [43]. Notably, hPSC-CMswere used to show that toxicity
was reducedwhen the anti-cancer drug, doxorubicin, was delivered via a
HER2-targeted liposomal pathway; this assisted the decision to advance
to Phase I testing [44]. Such studies have led the CIPA initiative (Compre-
hensive In Vitro Proarrhythmia Assay) to propose integration of hPSC-
CMs into the ICH (International Conference on Harmonisation) S7a/b
and E14 guidelines by the end of 2015. These guidelines have been the
mainstay over the last decade of preclinical assessment of cardiac electro-
physiology for new drugs [45].
Patient-speciﬁc hiPSC-CMs are being used increasingly to evaluate
altered phenotype and drug rescue of various channelopathies affecting
the heart, including long QT syndrome (LQTS)-1 [46–48],−2 [49–53],
−3 [54],−8 [55], LQTS3/Brugada overlap [56] and catecholaminergic
polymorphic ventricular tachycardia (CPVT) [57–59]. Disorders that af-
fect structure, contractility and survival have also been modelled, such
as Duchenne muscular dystrophy (DMD) [60], dilated cardiomyopathy
[61,62], hypertrophic cardiomyopathy (HCM) [63,64], Leopard Syndrome
[65], Barth Syndrome [66,67] and arrhythmogenic right ventricular
cardiomyopathy (ARVC) [68–71]. These have been used to understand
disease mechanisms and evaluate novel therapeutics. Thus, dantrolene
abolished isoprenaline-induced arrhythmias in CPVT1 hiPSC-CMs
[58], while trichostatin A was shown to prevent hypertrophy in
HCM hiPSC-CMs [64]. Tests for efﬁcacy of genetic intervention in-
clude oligonucleotide-mediated exon skipping and allele-speciﬁc
RNAi to correct DMD [72] and LQTS2 [53] hiPSC-CMs, respectively.
Most notably, the inability to manage effectively treatment of an in-
dividual with complex LQTS was addressed by deriving hiPSC-CMs
and performing multi-parameter in vitro drug testing until a suit-
able combinatorial regime was identiﬁed. This treatment was used
in the clinic to improve the patient's care [73] showing feasibility
of personalised medicine.
Nevertheless, while the examples above show the potential offered
by hiPSC-CMs, there are several reports of deﬁciencies relative to their
hESC derived counterparts. Thus, Foldes and colleagues [74] described
robust hypertrophic responses to phenylephrine in hESC-CMs but not
hiPSC-CMs. This was irrespective of the reprogramming or differentia-
tion method used. Indeed, a hESC line was differentiated to ﬁbroblasts,
which were reprogrammed to hiPSC. When this hiPSC line and the
parental hESC line were differentiated to CMs, only the cells derived
from hESCs showed hypertrophy, despite the cells sharing the same ge-
notype. Similar issues have been reported for improper reprogramming
and disease modelling in hiPSC from patients with Fragile-X relative to
hESCs derived from pre-implantation genetic diagnosis embryos [75].
Beyond their in vitro use, hPSC-CMs are also being evaluated for
treatment of damaged of diseased heart. Pilot studies using hPSC-
CM engraftment into mouse, rat, guinea-pig and pig models of myo-
cardial infarction were escalated to pigtail macaque non-human pri-
mates in mid-2014 [29]. In the primate studies, 1 billion cryopreserved
hPSC-CMs were transplanted in a complex pro-survival cocktail to the
infarct site of each of 7 animals. Transplanted cells led to extensive
remuscularisation, accompanied by host vasculature perfusion, electro-
mechanical junction formation between graft & host, and synchronous
calcium transients. Nonetheless, there were two cautionary notes. While
the hPSC-CMs constituted a graft size of up to 5.3% of the left ventricular
mass, survival of transplanted cells was less than 10% (b108 of 109 cells)
despite the powerful pro-survival cocktail. Secondly, although the ma-
caques remained free of distress, continuous electrocardiogram record-
ings showed that all animals receiving hESC-CMs developed ventricular
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mate studies and results from transplantation into swine. In a study in
pigs [76], the tri-lineage differentiation potential of hiPSCs was exploited
to produce CMs, endothelial cells and smooth muscle cells. A total of 6
million cells (2million of each lineage)were complexedwith a 3D epicar-
dial ﬁbrin patch loaded with microspheres to allow prolonged release of
the pro-survival factor, insulin-like growth factor 1 (IGF-1). The complex
was then transplanted into a porcinemodel ofmyocardial infarction. Sim-
ilar to the primate study, over a 4 week period cell survival was around
9%, although without the ﬁbrin patch was reduced to 3–4%. Surprisingly,
given the low cell numbers transplanted (160-fold less than the primate
study), there were improvements in myocardial wall stress, metabolism
and contractile performance. However, distinct to macaques, develop-
ment of ventricular arrhythmias was not reported in the pigs; whether
this important difference is down to the animal model, cell types, num-
bers or preparation method, inclusion of different survival factors or
transplant route are now all questions that need to be addressed. More-
over, these reports have not included methods to improve vasculature
to the grafted cells and this will be a consideration for the future.
The preclinical studies have led to the ﬁrst clinical trial for the heart
using hPSC derivatives. Menasché and co-workers [77] sought to direct
differentiation from hESCs and then use immunomagnetic sorting to
isolate ISL-1+/SSEA-1+ cardiac progenitor cells. These were embed-
ded into a ﬁbrin scaffold, whichwas surgically delivered onto the infarct
area in a 68-year-old patient suffering from severe heart failure. At the
3 month follow-up stage, the patient showed no complications, such
as arrhythmias, tumour formation or immunosuppression-related ad-
verse events, but was symptomatically improved, wherein echocardio-
graphically showed the damaged region of the heart regained
contractility. The progress of this patient, and those who follow, will
be keenly awaited. Nevertheless, nearly a year on it is not clear whether
any further patients have been recruited to this trial, even though the
expected start and end dates are 2013 and 2017 to treat a total of 6 pa-
tients. This perhaps highlights the challenges of coordinating complex
processes of large scale cardiac progenitor cell production, surgical
procedures and immunosuppression regimenswith highly selective pa-
tient inclusion criteria. Thus, for inclusion, patients must display severe
left ventricular systolic dysfunction with left ventricular ejection frac-
tion (LVEF) ≤ 35% as assessed by echocardiography or scintigraphy
and have an echocardiography history of myocardial infarction with a
residual akinesia involving more than 2 of 16 contiguous segments.
They will show New York Heart Association (NYHA) Class III or IV,
despite optimal standard of care including diuretics and angiotensin re-
ceptor blockers and, if possible, beta blockers and aldosterone blockers,
as well as previous implantation of an automatic internal deﬁbrillator
associated to ventricular resynchronization [78]. If the current Phase I
trial continues to provide optimism as a new treatment route for pa-
tients, the issues of bioprocess, surgery and patient selection will
need to be reviewed carefully. Indeed, it will only be through larger
trials that true improvements in the patient's heart function can be
attributed to cell transplantation rather than natural recovery or im-
pact of past treatment (e.g. bypass surgery, drug treatment, ventric-
ular resynchronization).
1.5. Genome editing marks a new era for in vitro genotype modelling
Until hiPSC approaches provided a route to capturing awide range of
patient-relevant genotypes, reliance had been on establishing hESC
lines from pre-implantation genetic diagnosis (PGD) embryos [79] or
by gene targeting [80]. However, PGD is available for only a limited
number of genetic conditions, few scientists have access to these fa-
cilities and the use of embryos (even those that harbour detrimental
genetic lesions) is ethically sensitive in many countries. Similarly,
gene targeting by homologous recombination was initially achieved
in a few laboratories to create knockouts (e.g. HPRT1 to model of the
metabolic disorder, Lesch Nyhan syndrome [80]) or reporter constructsdownstream of developmentally important genes, such as NKX2.5 [81].
In rare cases, creation of isogenic pairswas used to study role ofmutations
in genes such as KCNH2, which underlies the sudden cardiac death condi-
tion of LQTS2 [82]. Further progresswas stymied because of low recombi-
nation frequency (1 in 106–109 cells) in most mammalian cells, which
made the generation of isogenic models almost unachievable because
this often requires biallelic targeting. However, progress in genome
editing tools now allows rapid engineering of the genotypes available in
hPSCs. If there is not the need for patient history to draw in vitro-in vivo
correlations, the speed, ﬂexibility, ease and low cost of gene targeting
will be used in preference to hiPSC reprogramming to capture speciﬁc ge-
notypes; indeed, in our own laboratory, this is the situation for some
diseases.
For gene targeting, it has been known for 25 years that introduction
of speciﬁc double strand breaks at the target locus can improve efﬁcien-
cy. In human cells, complexing the Fok1 endonuclease to a pair of zinc
ﬁnger nucleases (ZFNs) [83] allowed double strand breaks at a model
GFP locus in 293 T cells [84] and endogenous PIG-A locus in hPSCs [84]
resulting in targeting efﬁciency improvements of 200- to 2000-fold.
However, the complex design and construction for each ZFN attracted
a high commercial cost of USD $25,000. The advent of transcription
activator-like effector nucleases (TALENs) used the same principle as
ZFNs, relying on a dimeric protein-based DNA binding domain coupled
to endonuclease. Construction kits, such as GoldenGate [85] and FLASH
assembly [86], meant individual labs could produce their own TALEN
vectors and hence reduce costs by 20-fold relative to ZFNs. Moreover,
TALENs showed greater speciﬁcity in hPSCs, with less off-target activity
and toxicity in comparison to ZFNs [87].
The real breakthrough came with the development of the Cas9/
CRISPR (Clustered Regularly Interspaced Short Palindromic Repeat) sys-
tem (Fig. 1) [88] which is derived from various strains of bacteria and is
often described as their immune system. The adapted version of this
system relies on 100 base site-speciﬁc guide RNA (gRNA) to direct the
Cas9 endonuclease to the target site, which eliminates the need for
time-consuming production of DNA binding-endonuclease fusion pro-
teins [89]. Such approaches have been used to perform correction
methods using exon skipping, frameshifting and exon knock-in into
hiPSC lines carrying mutations in DMD, which underlie severe muscle
degenerative disease [90].
There have been several further reﬁnements in the Cas9/CRISPR sys-
tem (Fig. 1). Use of dual guide RNA/Cas9-Nickase (D10A) reduces off-
target activity to an almost undetectable level [91]. Moreover, pre-
synthesised in vitro transcribed gRNAs can be complexedwith recombi-
nant Cas9 protein and transfected by nucleofection, providing a rapid
route to gene knockout or small changes in sequence, including substi-
tutions [92]. Thus, in the absence of a homology domain, Cas9-induced
DNA cleavage leads to non-homologous end joining and causes inser-
tions or deletions, known as ‘indels’, that can cause gene knockouts
[93]. To induce base substitutions, small changes or deletions of up to
100 kbases, the conventional ~5–15 kb targeting vector can be replaced
with a ~ 100–120nucleotide single-strandedDNAoligo [94].With this ap-
proach, Kimet al. [92] showedup to 79% targeting efﬁciency inCCR5 locus
in human leukaemia K562 cell line, BJ ﬁbroblasts and H9 hESCs.
The recombinant Cas9 approach has other advantages. Since it is ac-
tive immediately upon entry to the nucleus but continues to function for
only 24 h, off-target effects and toxicities are low, while targeting
frequency is high and eliminates the need for drug selection. Our
own work corroborates these ﬁndings (Fig. 1). We used Amaxa 4D
nucleofection to deliver a combination of gRNA, recombinant Cas9
protein and 110-nucleotide single-stranded DNA oligo template
into ReBl-PAT hiPSCs, which resulted in a targeting frequency at
the β2-adrenoceptor locus of 33%, of which 25% of clones were
biallelic. Such efﬁciencies can be expected to rise further with the
ﬁnding that small molecules can enhance targeting by up to 9-fold
in hPSCs [95], which will ultimately lead to panels of isogenic pairs
in hPSCs to study disease mechanisms and therapies.
Fig. 1.Genome editing in hPSCswith the Cas9/CRISPR system. Panel (A) shows a timeline of the key events involved in adaptation of the Cas9/CRISPR system for use inmammalian cells. In
(B), non-targeted, parental undifferentiated hESCs (NT1) or derived CMs (NT2) express KCNH2 RNA (arrow), which encodes components of the Ikr channel. These hESCs were targeted
with a construct that induced a G1681A SNP conversion in the coding region of the KCNH2 locus, whilst concurrently introducing a FRT-ﬂanked blasticidin resistance cassette into the
neighbouring intron. The selection cassette was to facilitate selection of targeted clones and did not interfere with any known KCNH2 regulatory elements. However, correct expression
of the RNA was compromised to levels that were barely detectable in targeted hESC-CMs (T1) and undifferentiated hESCs (T2). Only when the selection cassette was removed by Flp
recombinase was expression of the correct transcript size restored (T3). Panel (C) shows oligonucleotide-mediated gene editing in the absence of drug selection in hESCs at the ADRB2
locus, which encodes the b2-adrenoceptor. Transfection of hESCs was by Amaxa 4D nucleofection to introduce recombinant Cas9 protein complexed with an in vitro transcribed gRNA
and a single-stranded 110 base DNA oligonucleotide carrying an XbaI restriction site plus TAA stop codon. This enables functional knock out of targeted allele(s) and detection of targeting
events by RFLP (restriction fragment length polymorphism) analysis of clones. Incubation of PCR products with XbaI enzyme show non-targeted clones as a non-digested band
(i); heterozygote clones as three bands,indicated by single * showing non-targeted (band i) and targeted (digested bands ii/iii) alleles; or homozygote cells as two bands, indicated by
double ** showing both alleles targeted (digested bands ii/iii). Efﬁciency of targeting was 8/24 (33%) clones, of which 2/8 (25%) were homozygote. L = 100 bp Ladder.
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targeting will mark a step-change in gene editing. By avoiding the
need for a selection cassette eliminates the need for residual transgenic
DNA sequences to reside in the genome. Even by placing the selection
cassette in the intron, we have shown this can interferewith the expres-
sion of the KCNH2 endogenous gene in undifferentiated hPSCs and
derived CMs (Fig. 1). Only by excising the selection cassette with Flp
recombinase was endogenous gene expression restored (Fig. 1). Never-
theless, this strategy still leaves residual FRT recombination sites in the
genome. An alternative route to producing isogenic footprint-free hiPSC
models was used to achieve biallellic targeted correction of AATD (α1-
antitrypsin deﬁciency). After using ZFNs to target a construct containing
a drug selection cassette and the sequences to correct the polymorphic
mutation, the selection cassette was seamlessly excised via transposase
acting on ﬂanking PiggyBac transposons [96]. However, this two-step
approach requiresmore time andmore population doublings, which in-
creases the likelihood of genome instability in the targeted hPSCs.
Advances in the Cas9/CRISPR system mean that there is now expo-
nential uptake of the technology, with over 20 publications a week
appearing in PubMed. Commercial providers are now offering the re-
agents to target every gene in the human andmouse genome, and pro-
jects are underway within the Wellcome Trust Sanger Institute to
produce panels of mouse ESC lines in which every gene in the genome
has been knocked out. Notably, the Cas9/CRISPR system was used in a
somewhat abortive and controversial [97] attempt to target the β-
globin gene in human embryos. However, the efﬁciency of targeting
was low (14%), edited embryos were mosaic and the level of off-
target events was high due to homology with delta-globin gene
[98]. Inevitably, the debate will continue on the relative efﬁciencies,
ﬁdelities and off-target characteristics of each nuclease-based plat-
form. However, unpublished data indicate that the Cas9/CRISPR
elicits gene editing at up to 10-fold greater frequency than TALENs,
whilst off-target events are comparable between the systems when
constructs or gRNAs are produced to current best practise. It can
be expected that these next generation genome engineering ap-
proaches will start to provide the tools required to decipher thephenotypic impact of polymorphism data arising from GWAS
(genome-wide association studies).
1.6. Current and future technology challenges for hPSC-CMs
In the last 3 years, there have been considerable advances in the
methods to produce hiPSCs and genome engineer hPSCs. Concurrently,
improved protocols for differentiation have yielded novel approaches in
safety assessment,modelling disease, developing patient-speciﬁc thera-
pies and transplanting cardiac progenitor cells into the diseased heart.
Nevertheless, the technologies are still very much in the development
phase. The next sections consider some of the challenges facing the
ﬁeld of hPSC-CM biology, along with current progress.
2. Immaturity of hPSC-CMs
Reports from academia and industry show that hPSC-CMs display
phenotypes consistentwith a variety of disease- or drug-induced states.
Nevertheless, it is now well established that current differentiation
protocols produce cells with an immature phenotype consistent with
mid-gestation of human foetal heart development [13]. The consensus
viewpoint in the ﬁeld is that each improvement made to hPSC-CM
maturity will further increase utility. Table 2 provides a summary of
parameters collated from the literature (for speciﬁc details see [13,
99–104]) and/or generated by our own lab reﬂecting the differences be-
tween hPSC-CMs and adult CMs, providing a benchmark to measure ef-
fectiveness of prospective maturation approaches.
Structurally (Table 2), hPSC-CMs are round or multi-angular, small
cells with a single nucleus and show chaotic alignment. They have
disorganised and short sarcomeres (1.6 μm), an aspect ratio of 2 or 3:1
and no T-tubules. Most commonly, only Z-discs and I-bands can be
detected during microscopic analysis. Conversely, adult CMs are highly
organised, large rod-shaped poly-nuclear cells with sarcomeres of
2.2 μm and show longitudinal alignment. They have an aspect ratio of
5 to 9.5:1 and prominent T-tubules. Microscopic analysis shows Z-
discs, and I-, H-, A- and M-bands.
Table 2
Comparison of characteristic between adult-CMs and hPSC-CMs, showing the latter lack maturity.
Adult-CM hPSC-CM
Structure
Structure Rod-shaped Round or polygonal
Alignment Longitudinally aligned Chaotically organised
Nucleation ~30% cells bi- or poly-nuclear Very limited bi-nucleation
Sarcomere organisation Highly organised Disorganised
Aspect ratio 5–9.5:1 2–3:1
Banding Z-discs, I-, H-, A- and M-bands Mainly Z-discs and I-bands
Sarcomere length 2.2 μm 1.6 μm
SR
Sarcoplasmic reticulum Well developed Mixed response: caffeine, Thapsigargin & ryanodine
SR proteins e.g. CSQ, PLN, RYR2, SERCA/ATP2A2 Expression lower than adult
T-Tubules Yes No
Expr. Gene expression
MYH7 (β-MHC) NMYH6 (αMHC)
TNNI3 (cTnI) N TNNI1 (foetal ssTnI)
MYL2 (MLC2v) NMYL7 (MLC2a)
Titin isoform N2B predominates
ADRA1A (α-adrenoceptor) expressed
MYH6 (αMHC) NMYH7 (βMHC)
TNNI1 (foetal ssTnI) N TNNI3 (cTnI)
MYL2:MYL7 ratio not determined
Titin isoform N2BA predominates
ADRA1A (α-adrenoceptor) not expressed
Energy & force
Metabolism Mainly fatty acids Glucose and lactate but can use fatty acids
Energy production Mainly oxidative phosphorylation Mainly oxidative phosphorylation
Mitochondria Throughout cell; occupies 20–40% of cell volume Near nuclei; numbers increase during differentiation
Beating Quiescent Many cells spontaneous
Force
40 to 80 mN/mm2 (muscle strips)
~μN range (single cells)
0.08–4 mN/mm2 (3D constructs)
~200 nN (single cells)
Conductn
Capacitance 150 pF 20–50 pF
Resting mem potential −80 to−90 mV −20 to−60 mV
Upstroke velocity 150–350 V/s 10–50 V/s
Conduction velocity 60 cm/s 10–20 cm/s
Location of gap junctions Intercalated discs Circumference of cells
Ion channel density (pA/pF) INa −196 −100 to−244
ICaL −4.3 to−10.2 −2.2 to−10
Ito 2.3 to 10.6 2.5 to 13.7
IKs 0.18 to 0.58 Most publications 0.3 to 0.7
IKr 0.5 0.4 to 0.8
IK1 −12 0 to−3.4
INCX 2.5 to 3 3.6 to 7.9 (inward mode)
Ca2+ kinetics
APD90 260 ms 300–700 ms
Cycle Length 0.8–1 s 0.8–2 s
T-rise 2.5 ms 3.5-10 ms
Triangulation 45 ms 45-120 ms
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A recent report that showed gene expression in hPSC-CMs was similar to
that seen in theﬁrst trimester foetal heart [99].Moreover,MYH6 (αMHC),
TNNI1 (foetal ssTnI) and Titin isoform N2BA predominate in hPSC-CMs,
whereas it isMYH7 [βMHC], TNNI3 [cTnI] and Titin isoform N2B in adult
CMs. Low levels of calsequestrin, phospholambam, ryanodine receptor
and SERCA are reported for hPSC-CMs. This is corroborated by relatively
little sarcoplasmic reticulum (SR) and mixed responses to caffeine,
Thapsigargin & ryanodine.While in both hPSC-CMs and adult CMs oxida-
tive phosphorylation predominates and fatty acids can be used as an en-
ergy substrate, hPSC-CMs rely more heavily on glucose and lactate. In
adult CMs, mitochondria are located throughout the cell and occupy
20–40% of the cell volume, which contrasts to hPSC-CMs, where numbers
are lower and location is perinuclear.
Electrical immaturity of hPSC-CMs is evident from spontaneous
beating, since mature adult ventricular CMs are quiescent. This belies
high expression of the pacemaker current, If, and low expression of in-
wardly rectifying potassium current, IK1, which stabilises the resting
membrane potential to around -85 mV in adult cells; the value is−20
to -60 mV in hPSC-CMs (Table 2). Density of IKs potassium and INa sodi-
um channels is highly heterogeneous and can be lower than in adult.
Indeed, the presence of the IKs channel in hPSC-CMs, or the right tools
to detect it, has recently been called into question [105]. This is of partic-
ular concern since CIPA [45]will require these currents in addition to IKr
and ICaL. Collectively, these currents usually provide a capacitance of 30-
50 pF versus ~150 pF in adult CMs and upstroke velocity of 10-50 V/s
versus 150-350 V/s. Conduction velocity is also slower in hPSC-CMs
(10–20 cm/s versus 60 cm/s) on account of gap junctions being located
around the cell circumference rather than at the intercalated discs.2.1. Improving maturity of hPSC-CMs
The immaturity associated with hPSC-CMs is delaying progress in
the ﬁeld. The observation that hPSC-CMs undergo structural and
functional maturation when transplanted into the working myocar-
dium of model species shows the cells can mature when placed in an
appropriate environment [106]. Consequently, many investigators
are evaluating physical, chemical, genetic and environmental inducers
to facilitate maturation (Fig. 2). Current protocols typically produce beat-
ing clusters of CMs by day 6–12 of differentiation and gene expression
continues to mature over time. While some reports indicate expression
of speciﬁc pathways (e.g. β2-adrenoceptor [62]) or global transcriptome
[107] largely stabilises between 4 and 8 weeks of differentiation, others
have shown improvements in ratiometric markers (e.g. ssTnI:cTnI
isoform conversion) continue to occur for periods of up to nearly a
year [102]. Extended time in culture has also been shown to improve
ultrastructure of the sarcomere, calcium handling and ion channel ex-
pression [13].
Although it is not feasible to use extended culture for routine bio-
medical application, it does provide a useful developmental tool. Thus,
hESC-CMsmaintained in culture for a year showedmolecular signatures
similar to those seen for in vivo-derived mature cardiac tissues [108].
The data identiﬁed let-7 as the most highly up-regulated microRNA in
the culture-matured hESC-CMs. The authors went on to show overex-
pression of let-7 family members enhanced cell size, sarcomere length,
force of contraction, and respiratory capacity in hESC-CMs. It was also
suggested that the mechanism of let-7-driven maturation may be via
down-regulation of the phosphoinositide 3 kinase (PI3K)/AKT protein
kinase/insulin pathway and an up-regulation of fatty acid metabolism
Fig. 2. Schematic of in vitromaturation strategies for hPSC-CMs. (A)Methods include biophysical stimuli such asmechanical cues, electrical stimulation, optimising substrate stiffness and
topography. Biochemical cues can bepresented as soluble factors or substrate ligandswithin biological or syntheticmatrices. Geneticmanipulation such as forced expression ofmissing ion
channels has also been adopted as a maturation strategy. (B) The aim of these strategies is to drive the polygonal morphology and disorganised myoﬁbril banding of immature CMs
towards a more mature state indicated by rod shaped morphology and parallel myoﬁbrils (see also Table 2).
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machinery, such as miR-1, calsequestrin or Kir2.1 have also facilitated
maturation of hPSC-CMs [13].
2.2. Maturation: medium additives
Adding supplements to the culture medium is potentially a straight-
forward way to modulate hPSC-CM maturation. Table 3 shows factors
that have undergone some level of testing in mouse and human cells
to evaluate their ability to induce CM maturity. Triiodothyronine (T3)
is essential for normal cardiac development and during the perinatalTable 3
Factors with potential for facilitating maturation hPSC-CMs.
Factor Known function Model s
Insulin Regulates glucose uptake and postnatal cardiac growth
ARVD hIBMX Induction of adipogenesis
Dexamethasone Induction of adipogenesis
Corticosterone
Structural and functional maturation of the foetal heart
in vivo
Mouse
cardiom
PPARα Regulator of fatty acid metabolism in adult CMs ARVD h
PGC-1α (PPARγ
coactivator 1α)
Promotes cardiac mitochondrial biogenesis hESC-C
Klf15
Glucocorticoid receptor target that interacts with PPARα
to regulate cardiac lipid metabolism
Cardiac
from m
13-HODE Component of oxidised low-density lipoprotein via PPARγ
ARVD hRosiglitazone PPARγ activator that increases adiponectin in CMs
Indomethacin Mediates agonists for PPARγ to regulate adipogenesis
Insulin-like growth
factor
IGF1 receptor induces heart growth via the PI3K pathway mESC
T3 Thyroid hormone essential for optimal heart development hiPSC-C
EPA Fish oil that affects developmental bioenergetics mESC
Abbreviations: IBMX, 3-isobutyl-1-methylxanthine; ARVD, arrhythmogenic right ventricular dy
decadienoic acid; T3, Tri-iodo-L-thyronine; EPA, eicosapentaenoic acid.period, it regulates isoform switching of severalmyocardial proteins, in-
cludingMHCand titin. Incubation of hPSC-CMswith T3 for 1–2weeks led
to changes consistentwithmaturation, including 11-fold up-regulation of
αMHC, lower proliferation rates (but not increased bi-nucleation), 1.5-
fold increase in twitch force (to ~12nN/cell), higher calcium-derived
maximal upstroke and decay velocities enhanced oxygen consumption
rates [109].
An alternative approach was taken byWen and colleagues to model
the late onset disorder, arrhythmogenic right ventricular dysplasia
(ARVD) [110]. A combination of insulin, dexamethasone (a glucocorti-
coid) and IBMX (3-isobutyl-1-methil-xanthine; a phosphodiesteraseystem Effect Ref
iPSC-CM
Induction of adult-like metabolism in model of adult onset
disease
[70]
foetal
yocytes
Improve contractility, Z-disc assembly, mature myoﬁbrils
and mitochondrial capacity
[207]
iPSC-CM
Co-activation of PPARα and PPARγ promoted lipogenesis,
apoptosis & channel deregulation
[110]
M
Controlling PGC-1α and reactive oxygen species implied in
recapitulating mature phenotypes
[208]
progenitors
ouse hearts
Cells with plakoglobin mutation showed increased Klf15,
CEBPα, Wnt5b
[209]
iPSC-CM
Induced lipogenesis and apoptosis in model of adult onset
disease
[70]
Insulin or IGF1/2 during early differentiation increased
mesodermal cell proliferation
[210]
M T3 drives maturation [109]
Increases in gene expression associated with cardiac
development
[211]
splasia; PPARα, peroxisome proliferator-activated receptorα; 13-HODE, 13-hydroxyocta-
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acid synthesis and triggering activation of PPARα, which led to en-
hanced mitochondrial oxidative phosphorylation. Further addition
of the PPARγ activators, rosiglitazone and indomethacin, to the medium
caused abnormal PPARγ activation in ARVD hiPSC-CMs. This unveiled
the pathological phenotypes associated with this condition, which in-
clude exaggerated lipogenesis, apoptosis, Na+ channel down-regulation
and defective intracellular Ca2+handling. However, it is unlikely thatme-
dium additives alone will induce complete maturation of CMs, hence the
effect of modulating other components of the cell environment are being
investigated.
2.3. Maturation: biophysical cues
Unlike the hESC-CMs, primary CMs in the atria and ventricles of
adult human heart do not exhibit spontaneous beating. Instead, they
are innervated by the autonomic nervous system via nodal CMs,
which determines pace and contractility. To mimic this excitation–con-
traction coupling, Radisic and colleagues applied extrinsic electrical
ﬁeld stimulation to neonatal rat ventricular myocytes (NRVM) [111].
Compared to non-stimulated cells, ﬁeld stimulation induced elongated
morphology concurrent with increased sarcomere volume and num-
bers of mitochondria, intercalated discs, gap junctions and contractility.
Thiswork has been translated to hPSC-CMs [112],wherein three dimen-
sional (3D) conﬁgurations have been subjected to electrical ﬁeld stimu-
lation of increasing frequency (see 3D engineering section below).
Other investigators have assessed the impact of mechanical cues to
mimic the intra- and extra-cellular stresses that CMs experience. This
can be achieved by altering cyclic stretch,mechanical load and substrate
stiffness. Thus, Mihica and co-workers [113] reported hESC-CMs seeded
onto gelatin-based scaffolds and stressed with cyclical stretching
showed several hallmarks of maturation, namely, cell elongation, in-
creased expression of gap junction proteins and ion channels,while imag-
ing conﬁrmed shorter calcium cycle durations. Implantation of the hPSC-
CM constructs under the epicardium of ischemic rat hearts demonstrated
enhanced survival and engraftment in the stretched constructs.
Modulating substrate stiffness provides an alternative route to
varying the level of load experienced by the CMs. The rationale is that
substrate stiffness of the myocardium changes dynamically during de-
velopment. In the mouse, the elastic modulus increases from 12kPa in
the embryonic heart to 39kPa in the neonate [114]. In the human
heart, the modulus is 10kPa at the start of diastole but increases to
500kPa at the end [115]. While these dynamic ranges are known to
exist, there is considerable variation in the literature as towhat the ‘cor-
rect’ range of elastic moduli to translate from in vivo to in vitro. When
cultured on substrates that mimic the elasticity of the developing myo-
cardium (i.e. 1-11kPa, values for rat and quail), CMs from chicken em-
bryos produced contractile force and developed actomyosin striations
[116]. In contrast, CMs cultured on harder substrates (34kPa) designed
to mimic post-infarct ﬁbrotic scar tissue cells overstrained themselves,
lack striated myoﬁbrils and stop beating [116]. For neonatal rat ventric-
ular CMs cultured on hydrogels of 90kPa elastic modulus, there was a
high level of sarcomeric content and microtubule polymerisation rela-
tive to cells cultured on 13kPa hydrogels [117]. The same study also
showed that peak systolic force was generated from CMs seeded to
micro-patterned shapes of ~7:1 aspect ratio/13kPa substrates but ~2:1
aspect ratio/90kPa substrates [117]. In another report, neonatal rat ven-
tricular CMs cultured on collagen-coated polyacrylamide gels with an
elastic modulus 10kPa showed enhanced maturation, as evidenced by
increases in sarcomere alignment, mechanical force, improved calcium
transients and sarcoplasmic calcium stores relative to cells on substrates
with higher elastic moduli [118]. Most recently, single hPSC-CMs were
cultured on 10kPa polyacrylamide substrates patterned with Matrigel
in 2,000μm2 rectangles of aspect ratio between 5:1 and 7:1. The key
ﬁndings were that translation of sarcomere shortening to mechanical
output was highest in 7:1, while increased substrate stiffness or appliedoverstretch perturbedmyoﬁbril structure andmechanical output in 7:1
hPSC-CMs [119]. It is possible these discrepancies reﬂect the different
approaches used to measure elastic modulus or differences in the cell
types, as well as their isolation and culture methods. Irrespective of
the reasons, the diversity of data makes it difﬁcult to pinpoint conclu-
sions and a careful analysis of the impact of elastic modulus on hPSC-
CM function is needed.
2.4. Maturation: chemical cues from the substrate
The substrate chemistry and structure can have a signiﬁcant inﬂu-
ence on thematurity of hPSC-CMs. It is known that different extracellu-
lar matrices can inﬂuence structure and cell behaviour, with
phenylephrine-induced maturation absent when neonatal rat ventricu-
lar CMs were cultured on gelatin but present on ﬁbronectin or laminin
[120]. This has prompted investigations into the impact of synthetic
polymers on hPSC-CMs. A library of combinatorial polymers was used
to identify a mixture of 4% polyethylene glycol:96% carboxylated PCL
as enabling the greatest level of contractility and mitochondrial func-
tion. This was concurrent with increases in expression of MLC2v and
integrin α7, as well as a modest level of isoform switch from foetal
ssTnI to the postnatal cTnI [121]. Patel and co-workers [122] screened
almost 700 polymers for their utility as growth substrates for hPSC-
CMs. These were reﬁned down to identify chemically-deﬁned methac-
rylate co-polymers (isobornyl and tert-butylamino-ethyl) on which
hPSC-CMs exhibited a 6-fold faster upstroke velocity and signiﬁcantly
longer sarcomeres relative to gelatin controls. This copolymer also en-
hanced detection of the anti-cancer drug, doxorubicin, by up to 10-fold
when myoﬁbril disruption was used as the parameter for cardiotoxicity.
Combining substrates and enhanced maturation medium has also
been investigated. Single hPSC- or second trimester human foetal-CMs
were seeded to gelatin patterned lines on an acrylamide substrate load-
ed with ﬂuorescent beads, which allowed measurement of contraction
force [123].While hPSC-CMs showed distinctly lower contraction stress
than the foetal counterparts (~0.25mN vs ~0.4mN/mm2), incubation
with a proprietary commercial medium containing T3 promoted
contraction force to beyond that seen in the foetal cells (~0.5mN vs
~0.4mN/mm2). Concurrently, there was evidence of improved electro-
physiology (upstroke velocities, action potential amplitudes, resting
membrane potentials), sarcomeric organisation and cardiac-speciﬁc
gene expression.
Nevertheless, while these improvements are encouraging, the data
showed that the hPSC-CMs mirror the late-stage foetus rather than
the adult myocardium.
2.5. Development of muscular thin ﬁlms (MTFs)
Notwithstanding the variables above, relative to unpatterned
substrates, hPSC-CMs seeded onto ﬁbronectin-coated micro-grooved
polydimethylsiloxane (PDMS) scaffolds (~1.8 MPa) showed cellular
alignment, sarcomeric organisation, enhanced calcium properties and
heightened responses to caffeine, suggesting improved cycling [124].
Micro-patterned PDMS can also be incorporated into muscular thin
ﬁlms (MTFs), which have tunable stiffness and ﬂexibility to mimic
healthy as well as diseased myocardium conditions [125]. Shortening
of CMs during synchronous contraction causes the MTF to ﬂex and
adopt a pseudo 3D conformation, thereby enabling the force of contrac-
tion to be calculated [126]. The MTF platform has been used to evaluate
function of various cell types. Feinberg and co-workers [127] investigat-
ed the impact of architectures comprising isotropic (ISO) monolayers,
anisotropic (ANISO) monolayers and 20 μm wide 20 μm spaced lines
(LINES) on neonatal rat ventricular CMs. Relative to the ISO conﬁgura-
tion, ANISO and LINES showed uniaxial alignment, enhanced calcium
handling and conduction velocity, and a 10-fold increase in peak systolic
stress [127]. Treatment of human umbilical arterial vascular smooth
muscle cells as an anisotropic monolayer on MTFs showed application
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~22kPa [128]. The same study went on to show MTFs seeded with
neonatal rat ventricular CMs generated a peak systole stress of ~9kPa,
similar to contractility measurements performed on papillary muscle
from adult rats [128].
The MTF platform has been extended to modelling of themitochon-
drial myopathy, Barth syndrome, which is caused by mutations in the
X-linked gene, Tafazzin (TAZ). Patient-derived hiPSCs with mutations
in TAZwere differentiated to CMs and cultured as self-organising lami-
nar, anisotropic MTF myocardium constructs for “heart-on-a-chip”
analyses [129]. Control CMs showed better sarcomeric alignment than
the disease samples. During electrical ﬁeld stimulation from 1 to 5 Hz
in galactose-containing medium, control hiPSC-CM MTFs produced a
twitch stress of 250 Pa relative to the signiﬁcantly weaker values of
100 Pa in the diseased tissues. This recapitulated the Barth Syndrome
myopathic phenotype and provides a basis for further investigation of
the mechanisms that underlie the condition in the engineered tissue.
The development of MTFs that have electrodes incorporated for electri-
cal ﬁeld stimulation and micro-ﬂuidic channels for drug loading will
allow the platform to be used for cost-effective and scalable for pharma-
cological testing [126].
Nevertheless, 2D systems and MTFs lack the structure of the adult
heart. In part, this may be due to improper cell attachment to the sub-
strate. Bidirectional translation of mechanical forces between the con-
tractile apparatus and ECM is governed by integrins [130]. While there
are similarities in integrin expression between adult-CM and hPSC-
CMs, the adult cells typically attach to surfaces with their distal cellular
regions (costameres integrin rich area) [131], whereas hPSC-CMs form
integrin attachments along their basal surface. In addition, sarcomeres
in adult-CMs are aligned in perpendicular direction from the cell axis,
which results in higher probability of actin-myosin cross-bridge forma-
tion and hence greater contractile force. Collectively, these differences
lead to different mechanotransduction mechanism and contractility pat-
terns between adult- and hPSC-CMs. It may be that nano-patterning the
substrate could promote better adhesion and alignment in hPSC-CMs
and will need to be tested.
2.6. Engineering heart tissues in three dimensions
In parallel to the development of the various 2D and MTF systems
available, 3D approaches to incorporate hPSC-CMs have been investi-
gated. The 3D systems that have been validated to a higher level include
engineered heart tissues (EHTs [132]), cardiac microtissues (CMTs or
microtissue gauges; μTUGs [133]) and cardiac biowires [112]. EHTs
and CMTs rely on casting cell-hydrogel mixtures in moulds featuring
elastic anchors that guide cardiac tissue organisation in an aligned con-
formation. This enables the CMs to perform contractile work against the
anchors, thus developing an auxotonic tension that resembles physio-
logical conditions. EHT fabrication involves encapsulating CMs in ﬁbrin
gels between two silicon posts, whereas CMTs are based on CM-
seeded ﬁbrin/collagen gels tethered to PDMS cantilevers. Functional
evaluation of CM contractility can be monitored indirectly in the EHTs by
video-optically analysing the deﬂection of the silicon posts with known
mechanical properties. In CMTs, direct force reporting is via a micro-
electromechanical sensor coupled to the cantilevers. Importantly, CMs
in these systems can be loaded with calcium- or voltage-sensitive dyes,
enabling functional analysis of calcium transients and electrophysiology
[134]. Cardiac biowires consist of a cell-laden collagen gel around a surgi-
cal suture placed in a PDMS mould.
These 3D systems each have pros and cons. EHTs and biowires are
produced in centimetre-scale that require 0.5–1 million CMs per unit.
For EHTs, format is 24-well requiring 12–24 million hPSC-CMs, which
is costly at current commercial rates of USD$1000/million cells. In con-
trast, a million cells are sufﬁcient to produce 100–200 microscale CMTs
and so 96-well formats are feasible. Measurements in EHTs are possible
over several weeks, potentially enabling acute and chronic drug effectsto bemonitored,whereas long-termanalysis in CMTs ismore difﬁcult as
they are harder to handle. Dynamic load of the silicon posts in EHT and
cantilevers in CMTs can be varied tomimic heart failure. Biowires do not
permit measurement of contractility, which is a major disadvantage.
The 3D conﬁguration has been shown to enhance CM maturation.
CMs in EHTs align along the force lines between the silicon posts, with
3.4-fold improved longitudinal orientation relative to embryoid body-
CMs. Sarcomeres in the EHTs become evenly distributed both around
the nuclei and in the periphery of the cells, although connexin-43 is
still expressed along the sarcolemma (unlike adult CMs that express
this gap junctional protein in the intercalated discs). Elevated expres-
sion of adult isoforms of sarcomeric genes (e.g. MYH7 encoding β-
MHC) also occurs. EHTs display key responses to physiological and
pharmacological stimulation, such as increased contractile forces at
higher extracellular Ca2+ concentrations and upon treatment with β-
adrenergic agonists [135]. CMTs developed with hESC-CMs promote
cell alignment and expression of mature CMmarkers such as BNP.
These improvements in maturation appear to be further enhanced
by incorporating electrical stimulation, even if not always as anticipated.
Beat rate is ~3 Hz in human foetal hearts beat but ~1 Hz in adults. This
suggests that reduction in rate might correlate with maturation but the
opposite was observed in hPSC-CMs. Thus, increasing stimulation fre-
quency from 1 to 6 Hz in hPSC-CM biowires caused maturation, as evi-
denced by improvements in structure and function [112]. It may be that
forcing mechanical stress by pacing is more important than the electri-
cal stimulus per se. Nevertheless, stimulated biowires had myoﬁbrils
with a higher degree of ultrastructural organisation (aligned Z-discs
displaying up to two I-bands per disc; organised sarcomeres showing
up to 0.4-H zones per sarcomere) and enhanced expression of cardiac
contractile proteins, such as sarcomeric α-actinin, actin and cTnT. Con-
duction velocity increased (~15 vs ~10 cm/s) and therewas greater sar-
coplasmic reticulum maturity, with caffeine treatment resulting in
higher cytosolic Ca2+ transients. Electrical stimulation of biowires in-
duced higher IKr (~0.81 vs 0.52pA/pF) and IK1 (~1.53 vs 0.94pA/pF) cur-
rents [112]. Similar data have been created for hPSC-CM derived EHTs,
wherein electrical stimulation improved Ca2+ transients, contraction
force and response to isoprenaline [134].
Nevertheless, 3D platforms have not produced fully mature CMs
and are absent for properties including (i) formation of T-tubules,
(ii) expression of the full array of sarcomeric proteins (including α-
sarcomeric protein and myosin-binding protein C), (iii) physiological
potassium ion channel densities, and (iv) contraction forces. For exam-
ple, infarcted heart muscle has a twitch force of 40–80 mN/mm2, which
is ~30- or 600-fold greater that EHTs comprising rat-CMs (2-4mN/
mm2) or hPSC-CMs (0.08–0.12mN/mm2) [136]. Whether these param-
eters can be improved by combining electrical pacing, medium supple-
mentation with adrenergic agonists, thyroid hormones and growth
factors and/or co-culture with supporting cell types (e.g. cardiac ﬁbro-
blasts [137]) requires further investigation.
As well as use in vitro, the utility of EHTs in correcting myocardial
function deﬁcit in animal models of heart failure has been tested. Most
studies have used allogeneic transplantation of rat EHTs or xeno-
grafting of human EHTs into myocardial infarcted immunosuppressed
rats. By 4–12 weeks post transplantation, ~25–30% of grafted cells sur-
vive intervention [138,139] and show electrical integration without ar-
rhythmias [140]. Of note, EHT-grafted hearts showed maximum
conduction velocities similar to non-infarcted rat myocardium (VT =
0.19 m/s vs VT= 0.16 m/s, respectively) and host-derived angiogenesis
with a ~ 2.8-fold increase in vascular density in the EHT-borderzone re-
gion [139]. Grafted hearts showed slowing of disease progression, evi-
denced by improved fractional shortening and lower maximum left
ventricular volume [140]. Nonetheless, recovery of the infarcted heart
after EHT transplantationwas not to ‘healthy’ levels and additional chal-
lenges to overcome include: i) reducing immunogenicity of the graft by
developing deﬁned, xeno/serum-free culture and EHT fabrication
conditions; ii) scaling graft size to include the cell quantities (≥1010
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clude not only cardiomyocytes, but also smoothmuscle cells and cardiac
ﬁbroblasts. Further inclusion of endothelial cells should help to over-
come the important issues of vascularization, which could reduce the
levels of cell death seen in the transplanted EHTs [138]. Integration of
pre-formed vascular structures [141] or of additional extracellular ma-
trix (e.g. collagen +Matrigel) has already shown progress to improved
vasculargenesis of EHT-derived grafts in animal models of heart disease
[142] and will be an area to explore further in the future.
In summary, different physical, chemical, genetic and environmental
factors have been shown to mature hPSC-CMs in 2D and 3D conﬁgura-
tions. The varying successmay be due to biology or to differences in tech-
nique. Recent work by Du and colleagues showed that non-invasive
optical mapping of action potential morphology in hiPSC-CMs seeded as
conﬂuent monolayers or as sparse cultures did not predict cardiac cham-
ber speciﬁcity but, instead, was dependent on cell density [143]. Thus, es-
tablishing experimental standards will ensure greater comparability
between reports.
3. Towards industrial scalability of hPSC-CM platforms
Most of the studies described above have been carried out by indi-
vidual academic or industrial labs using less than 5 hPSC lines in con-
junction with low throughput technology to test low numbers of
parameters and so require only a fewmillion hPSC-CMs. For these tech-
nologies to be used as widespread commercial tools, there will be a
need to upscale culture and differentiation. Analysis of a hundred com-
pounds over 6 x ½ log doses for 10 replicates using existing 96-well cal-
cium imaging systems [144] or 24-well multiplexed EHTs [135] would
require approximately 500 million or 3 billion hPSC-CMs, respectively.
For in vivo use, recent studies have shown that transplanting 1 billion
hPSC-CMs into the infarcted hearts of pigtailed macaques led to sub-
stantial remuscularisation [29] but to achieve the same in the larger
human heart would require at least 10 billion CMs. Current commercial
rates for 1million hPSC-CMs costs are USD 1000, meaning at the in vitro
and in vivo scales above permitted budgets of most companies or
healthcare providers would be exceeded.
3.1. Scale-up of hPSC culture and CM differentiation
The three core requirements for adherent culture of hPSCs aremedi-
um, matrix and passaging method. The labour intensive nature of me-
chanical dissection of individual colonies was never compatible with
commercial upscaling and soon gave way to bulk passaging methods
[145]. Initially, clump passaging methods used collagenase, dispase or
cell scraping, but have largely been replaced by small clump passaging
with EDTA and by Accutase and TrypLE enzymes that produce single
cells or small clusters (2–5 cells). The latter enzymatic approaches are
compatible with single cell cloning needed for genome editing technol-
ogies and automated cell counting for integration of hPSCs into robotic
culture platforms.
Similar progress has been achieved with culture medium. Poorly
deﬁned serum, serum replacements and conditioned medium were
superseded by more reﬁned medium such as StemPro, Nutristem,
mTeSR and TeSR2 celiz [146], some of which were available as
“xeno-free” formulation and potentially compatible with clinical-
grade Good Manufacturing Practice (GMP). However, these media
often showed considerable batch to batch variability. Development
of Essential 8 (E8) has addressed this issue and is becoming the de-
ﬁned medium of choice for many laboratories. It can also be coupled
with Sendai-virus and Essential 6 medium to enable efﬁcient
integration-free reprogramming of somatic cells into hiPSCs and is
compatible with high efﬁciency monolayer differentiation of hPSCs
to CMs (see Table 1). Nevertheless, the high cost of commercially-
produced E8 (~USD $450 per litre) means many research labs areusing the published formulation to make their own medium for
around USD $70 per litre.
Perhaps the most challenging part of the culture system to deﬁne is
the matrix. Very few labs now rely on the early methods of using
mitotically-inactivated mouse or human feeder cells to support hPSC
cultures. However, use of cell derived (e.g. Matrigel, Geltrex) or recom-
binant (e.g. laminin, collagen, ﬁbronectin, vitronectin, E-cadherin) are
frequently used but are expensive, variable and/or labile [145]. De-
velopments in the ﬁeld have included formulation of humanised
versions of the proteins (e.g. CellStart), peptide-polymer conjugates
(e.g. Synthemax) and plasma-treated polystyrene. Recently, Celiz
and co-workers [145] employed a high throughput materials dis-
covery approach by microarray screening of 909 unique polymers
to identify the ﬁrst synthetic polymeric substrate that achieved
both hPSC expansion in commercially-available StemPro and mTeSR
media and subsequent multi-lineage differentiation, including to CMs.
Nevertheless, the compatibility of the polymer substrate with E8 was
not shown and the largest culture format was 6-well so further develop-
ment is needed.
In parallel with the development of improved culture systems, there
have been various attempts to evaluate the compatibility of culture pro-
tocols on automated liquid handling platforms for robotic scale-up of
hPSCs and their differentiated derivatives. Automated systems have
been shown to improve the consistency, quality and failure rates often
reported frommanual handling of cell cultures [147]. The CompacT Se-
lecT systemwas used to demonstrate feasibility of producing ~2.5 x 109
undifferentiated hESCs, although this early report used mouse embry-
onic ﬁbroblast conditioned medium coupled with Matrigel [148]. The
Biomek FXP liquid handler workstation has been used to automate the
cardiomyogenic differentiation of mouse ESC in a 384 well plate format
[149]. However, in a tour de force of automation Paull and co-workers
[150] development a modular system that enabled 1008 mRNA
reprogramming events from human adult and control ﬁbroblasts to be
processed in batches of 48 samples per run. This resulted in 221 suc-
cesses, as judged by presence of nascent TRA-1-60+ hiPSC colonies.
The automated systemwas used to induce spontaneous or directed dif-
ferentiation of several of the lines into lineages includingmidbrain-type
dopaminergic neurons, hepatocytes, metanephric mesenchyme and ol-
igodendrocytes. CMs were also produced at efﬁciencies of ~40–65%,
similar to cultures handled manually. In our own lab, we have dem-
onstrated the feasibility of automating large scale production of
hPSC-CMs in 90cm2 Roboﬂask™ format on a Tecan Evoware Liquid
Handling Platform (Fig. 3). This custom built system has a capacity
of ~100 x 90cm2 Roboﬂasks™, giving a potential maximum batch
production yield of ̴3 x 109 hPSC-CMs in a fully deﬁned and repro-
ducible manner.
An alternative route to scaling hPSCs and differentiated lineages is
the use of suspension bioreactors. Undifferentiated hPSCs have been
upscaled across 10 passages as multi-cellular aggregates in stirred
tank bioreactors in suspension [151], including in mTeSR or E8medium
[152], whilst retaining normal karyotype, expression of pluripotency-
associated markers and multi-lineage differentiation potential. While
it has been long-established that mouse PSCs can be differentiated in
stirred bioreactors to yield N3 × 109 CMs in stirred bioreactors [153],
only more recently have suspension cultures been successfully used
for cardiomyogenesis in hPSCs. Thus, in 100 ml bioreactors, batch and
cyclic perfusion controlled feeding strategies with induction of using
the GSK3 inhibitor, CHIR99021, produced 40 million hPSC-CMs [154].
Based on electrophysiology, 85% cells were ventricular subtype, al-
though nomolecular characterisation was performed and the use of ac-
tion potential morphology to assign subtype has been questioned
recently du [143]. Elegant work has also showed pipeline conversion
of mouse ﬁbroblasts into iPSCs and then into iPSC-CMs in a single sus-
pension bioreactor [155]. The challenge now is to translate the high ef-
ﬁciency ‘inducible secondary’ iPSC reprogramming into a technology
that is compatible with human cells.
Fig. 3. Fully automated Tecan Evoware Liquid Handling platform for hPSCs expansion and differentiation. Panel (A) shows the anatomy of the automated platform. hPSCs cultured in
92 cm2 Roboﬂasks™ (Corning®) (Ai) in tower stacks (Aii) within integrated 37 °C/5% CO2 automated incubators (LiCONiC Instruments) (Aiii). All media exchanges, cell dissociations,
hPSC counting and reseedings are fully automated on a liquid handling deck (Aiv) within a custom build class 2 cabinet (Bigneat Ltd) (Av). In (B), automated hPSC-CM differentiation
in monolayer yields populations that stain positive for α-actinin (Bi), with comparable purities between cultures produced by manual or automated processes, as judged by automated
image analysis to a-actinin (Bii) or ﬂow cytometry for cTnT or a-actinin (Biii).
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For in vitro assays, such as safety assessment, there will be a need to
integrate hPSC-CMs into existing or new platforms to assess cell function.
In parallel with issues above of hPSC-CM maturation, cell phentopying
is rapidly becoming a bottleneck. In the following sections, we consider
some of the platforms that have been (or might be) used for the
medium- to high-throughput measurement of structure, metabo-
lism, electrophysiology, calcium and contractility.
4.1. High content imaging
The use of high content imaging is an industry standard for assess-
ment of physiology of tumour cell with regards cell number, cell
shape/size, proliferation, viability, membrane integrity, phagocytosis,
apoptosis, cell migration, cell-cell contacts and organelle health (e.g.
numbers, size, shape, activity of nucleus, mitochondria, lysosomes)
[156]. Assays are typically carried out in 96-, 384- and 1536-well plates,
which are compatible with various fully automated platforms [157]
such as BD pathway (BD Biosciences), InCell Analyser (GE-healthcare),
ImageXpress (Molecular Devices), Opera (Perkin Elmer) and Cellomics
Arrayscan (ThermoFisher). For undifferentiated hPSCs, high content im-
agingwas used to screen putative chemicals for their ability tomaintain
pluripotency in the absence of growth factors or to improve cell survival
after passage [158,159]. Such approaches identiﬁed a series of inhibitors
of the Rho kinase pathway and pro-survival compounds such as Y27632
that are now used bymany labs during routine hPSC culture. A different
approach was taken to evaluate the inﬂuence of substrate chemistry on
pluripotency. By formingup to 2000microspots of 200–300 μmona sin-
gle microscope slide, 909 unique methacrylate-based polymers were
assessed for hPSC attachment and OCT4 expression in 4356 individual
assays. A polymer was identiﬁed that could support pluripotency by
using a combination of Imstar digital imaging, Operetta confocal imag-
ing and CellProﬁler software [145].
These imaging approaches have been extended to hPSC-CMs
(Table 4), allowing identiﬁcation of polymers that facilitate maturation
[122]. Further progress in using imaging to deﬁne hPSC-CM structure
was made by Pasqualini and co-workers [160]. Using commercial CDI
iCell and Axiogenesis CorAt hPSC-CMs stained for the sarcomeric protein,α-actinin, a set of 11metrics were developed to score the degree of orga-
nisation and alignment that sarcomeres acquire during myoﬁbrillo-
genesis, which were used evaluate phenotypic maturity. This parallels
our ownwork using the Operetta confocal plate reader platform to assess
sarcomere number and area within hPSC-CMs (Fig. 4).
High content imaging is now being used to evaluate the effect of
chemical insult on hPSC-CMs (Table 4). As examples, chemical induc-
tion of hypertrophy in hPSC-CMs by angiotensin II, phenylephrine, or
endothelin-1 has been evaluated in 96-well or 384-well plates. The
Cellomics Arrayscan was used to show that some aspects of the path-
ways underlying hypertrophy are defective in multiple lines of hiPSC-
CMs relative to hESC-CMs [74], while the ImageXpress Micro platform
was used to calculate the EC50 of enthothelin-1 as 11 pM in commercial
hiPSC-CMs [161]. Imaging was also used to examine hypertrophic re-
sponses of patient-speciﬁc hiPSC-CMs froma ten-member family cohort
carrying a hereditary hypertrophic cardiomyopathy missense mutation
(Arg663His) in theMYH7 gene [63].
For assessment of cardiotoxicity, Mioulane and co-workers [162]
triggered cell stress with the cell-permeable protein kinase C inhib-
itor, chelerythrine. Coupling staining cells with potentiometric dye
(TMRM; tetramethylrhodamine methyl ester), caspase-3 or BOBO-
1 with Cellomics Arrayscan imaging assessed mitochondrial func-
tion, apoptosis and cell death, respectively. Application notes from
CDI show quantiﬁcation of the cardiotoxic effect of valinomycin,
etoposide and rotenone in hPSC-CMs using high content imaging
of changes in mitochondrial and lysosomal physiology, DNA damage
and oxidative stress (cellulardynamics.com). Unpublished data pre-
sented by GE-healthcare show how 26 anti-cancer agents changed
19 different cell morphological and functional parameters in hPSC-
CMs, with analysis being carried out on 3 replicates, 2 timepoints
and 7 doses in a 384-well plate format using the InCell 2000 plat-
form. This analysis produced graphical proﬁle sets that were associated
with high, moderate, low or no drug-induced cellular toxicity. In an im-
pressive study, Sirenko and colleagues [163] used CalceinAM, Hoechst
and MitoTracker imaging on the ImageXpress Micro to evaluate
cardiotoxicity of 131 modulators of Na+, K+ and Ca2+ channels, as well
as adreno-, dopamine- and histamine-receptors on CDI iCell hiPSC-CMs
384-well format. This shows that using hPSC-CMs in high content imag-
ing has now become reality.
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Mitochondria can be inﬂuenced by developmental stage, disease
state and toxic insult. Hence, analysis of function in hPSC-CMs has
been evaluated to gauge maturity, model disease and quantify toxicity
(Table 4). As well as the imaging systems discussed above, function of
mitochondria can be determined bymeasuring glycolysis and oxidative
phosphorylation (OXPHOS), for which the preferred substrates are
glucose in immature CMs and fatty acids in mature CMs, respectively.
Initial platforms for evaluation were low throughput. This prompted
the development ofMitoXpress™, a long-decay phosphorescent oxygen
probe [164], which allows estimation of IC50 values of 25 drugs/day
using a 96-well format [165]. As an alternative platform, the Seahorse
Extracellular Flux Analysers uses 24- or 96-well custom plates to deter-
mine in vitro oxygen consumption rate (OCR) and extracellular acidiﬁca-
tion rate (ECAR) to assess OXPHOS, glycolysis and fatty acid oxidation.
These approaches have been used to conﬁrm a preference of hPSC-CMs
for glycolysis when cultured in medium containing glucose, consistent
with developmentally immature state. However, hPSC-CMs can undergo
some level of maturation by culturing in galactose/fatty acid-containing
medium to force transition towards OXPHOS or treating with T3 [109]
or overexpressing let7 miRNA family [108].
The Seahorse platform is now becoming a common tool in evaluating
disease state in hPSC-CMs (Table 4). Changes in OCR, ECAR, glycolysis,
fatty acid oxidation, maximum respiration capacity and ATP generation
have been studied in hPSC-CMmodels of Barth syndrome [67], Duchenne
muscular dystrophy [166], Pompe's disease [167], ARVD [70] and type I
diabetes [168]. Usually, this involves recording basal levels of activ-
ity from the hPSC-CMs and then subjecting them to a sequential
treatment of electron transport chain inhibitors (e.g. oligomycin, ro-
tenone, antimycin-A) or uncouplers (FCCP). The same approaches
are now being adopted for compound screening. Enzo Life Sciences
used Axiogenesis Cor.4 U hiPSC-CMs to measure oxygen consump-
tion and glycolytic ﬂux in real-time via oxygen and pH sensor
probes in 96- or 384-well to inform on drug induced toxicity and
mitochondrial function.
4.3. Electrophysiology and calcium
The use of sharp glass electrodes to access the cell interior via
conventional patch clamp electrophysiology is considered the gold-
standard for studying ion channel activity. No other technique offers
more insight into the functionality, kinetics, gating properties and phar-
macology of ion channels. However, the complexity of this low through-
put, labour-intensive approach allows only 10–15 data points a day,
which is insufﬁcient to meet the demands of both academic and indus-
trial labs. This has prompted the development of various platforms for
direct or indirect measurement of electrophysiology and/or calcium
ﬂux, which are now being applied to hPSC-CMs (Table 4).
4.3.1. Planar patch clamp electrophysiology
To overcome the low throughput of conventional sharp electrodes,
several ‘planar’ patch clamp platforms have been developed that can
process 16 to 384 multiple recordings in parallel. While these systems
differ in their technical speciﬁcations and level of automation, they in-
crease data throughput 10- to 100-fold depending on the ion channel
under investigation and the platform used [169]. By reducing the com-
plexity of the process, they alsomake patch clamping accessible tomore
users, regardless of previous experience in electrophysiology [170]. The
use of platforms including IonWorks Quattro [171], PatchXpress [172],
Patchliner [173], SynchroPatch [174] and Opatch [175] has been main-
stream for the analysis of recombinant cell lines overexpressing single
ion channels, and they are nowbeing trialled for usewithmore complex
hPSC-CMs [24,175–177] with varying degrees of success (Table 4).
The PatchXpress has been used with high purity hiPSC-CMs to si-
multaneously record from 16 channels [24]. The authors measureddensities of INa, Ica and IKr currents in the presence or absence of their
respective pharmacological inhibitors, tetrodotoxin, nifedipine and
E4031. However, the study used an engineered hiPSC line with a neo-
mycin phosphotransferse drug resistance cassette targeted down-
stream of the MYH6 (αMHC) locus to enrich the CMs, a strategy that
is not easily adopted acrossmultiple hPSC lines. Seal rateswere relative-
ly low at ~50% across 58 wells, as was the quality of the seal (~200
megaOhms [MΩ]). Genetically puriﬁed hiPSC-CMs have also been
used on the CytoPatch2 platform [178]. Analysis in current clamp
mode enabled retrieval of ventricular, atrial/nodal and S-type action po-
tentialmorphologies. By achieving seal resistances over 1GΩ, the action
potential durations of ventricular-like cells were shown to be decreased
by nifedipine and tetrodotoxin, but increased by cisapride [178]. In our
own work (submitted CD, DR), we have used high efﬁciency differenti-
ation protocols to produce CM purities of N80% across 6 healthy or dis-
eased hPSC lines. Processingwith the Patchliner platform enabled catch
rates of ~81%, seal rates of ~80% and seal qualities of up to N2GΩ. Anal-
ysis in voltage clampmode, allowed evaluation of INa, Ica,L and IK current
densities and proof of principle for pharmacological testing with tetro-
dotoxin, nifedipine and E-4031. These studies provide an initial demon-
stration that planar patch systems can be used to investigate speciﬁc
ionic currents in single hPSC-CMs.
4.3.2. Multi-electrode arrays (MEAs) and nanopillars
The invasive nature of planar patch permits only short-term
(minutes to hours) recordings from single cells. However, someapplica-
tions, including acute and chronic toxicity, may beneﬁt from long-term
recordings (days/weeks) from multi-cell clusters. Multi-electrode ar-
rays (MEAs) comprise glass slides photo-etched with arrays of micro-
electrodes that can record ﬁeld potentials from cell types for periods
from hours to days. Most analysis with MEAs has been done using low
throughput single-well formats using multi-cellular clusters of hPSC-
CMs in 2Dmonolayers or 3D structures, including evaluation of drug re-
sponses in hiPSC-CMs carrying KCNH2 (IKr) mutations that underlie
LQTS2 [51]. Nevertheless, there have been some reports of multiplexed
MEAs being used for evaluation of cardiotoxicity in hPSC-CMs (Table 4).
By seeding hESC-CMs to 4-well MEAs, ﬁeld potential duration (FPD)
was calculated after challenge with escalating doses of 12 cardiac or
non-cardiac drugs. This showed that the dose known to cause QT pro-
longation in patients corresponded with increases in FPD in hESC-CMs
[179]. In a follow-up paper, this approach was extended to evaluate
the effect of the IKs inhibitors, HMR1556 and JNJ303, on hPSC-CMs.
However, prolongation could only be detected when the high density
IKr current was reduced by pharmacology (dofetilide or sotalol) or ge-
netics (hiPSC-CMs with a mutation in KCNH2) [40], supporting the no-
tion that IKs is a weak current in hPSC-CMs [105]. Positive in vitro-in
vivo correlations have also been made with the hPSC-CM model being
used in conjunction with a 48-well MEA system. Recordings were
made 0.5, 1, 2 and 4 h post exposure to compounds with a combination
of IKr, QT and clinical proarrhythmia properties, including verapamil,
ranolazine, ﬂecainide, amiodarone, ouabain, cisapride and terfenadine
[180].
However, a contradictory report used theMaestroMEA Platform (1-
to 96-wells) to perform blinded evaluation of ﬁeld potential duration,
Na+ slope/amplitude, beat rate and early after-depolarizations to 15
IKr, INa or IKs blockers in hPSC-CMs (Table 4). The authors concluded
that these parameters were unable to distinguish torsadogenic from be-
nign compounds, with the suggestion that hPSC-CMs on MEAs would
have a high false-positive rate in regard to proarrhythmic risk [181]. It
is not clear why these discrepancies have arisen but will be important
to identify to ensure consistency of analysis in the MEA platform. It is
possible differences in cell seeding density or process reduces contact
with the electrode, which could reduce signal strength, quality and ac-
curacy of cellular action potentials recordings, as could the proportion
of quiescent CMs in the cell preparations [182]. Additional factors that
will need to be borne in mind as new generations of 96-well MEAs
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transmission, reducing plate cost and improved level of user-friendly
software interface that automates data analysis.
Recent technological improvements have allowed themerger of the
advantages of substrate-integrated extracellular MEAs with intracellular
electrodes. These switch between extra- and intra-cellular recordings
using vertical nanopillar electrodes capable of nano-scale electroporation
and re-sealing events.While such systems are capable of detecting action
potential waveforms of hPSC-CMs [183], the transient nature of the intra-
cellular recordings currently limits their use for drug screening purposes.
4.3.3. Optical imaging
The challenges of direct recording of electrophysiology or use of
impedance-based approaches have stimulated the development of opti-
cal mapping to measure action potentials and calcium wave propaga-
tion using voltage-sensitive dyes (VSDs) [184] like the ANEPPS dyes or
genetically-encoded voltage indicators (GEVIs) [185]. These techniques
allow action potential detection with high spatial and temporal resolu-
tion, and are amenable to scale-up. Fluorescence data can be easily and
rapidly acquired simultaneously from several cells in a single ﬁeld of
view, permitting the analysis of over 440 single hESC-CMs in a day
(Table 4) [186]. Furthermore, the potential to carry out sequential mea-
surements would allow each cell to be used as its own control helping
overcome the inherent heterogeneity of preparations of hPSC-CMs
(Herron et al., 2012).
Optical imaging has been used tomeasure calcium transients or beat
rates in hPSC-CMs, with high throughput platforms including FLIPR
tetra, ImageXpress Micro, FDSS/μCELL and CellOPTIQ in 96- to 384-
well formats (Table 4). In particular, the 96-well cellOPTIQ showed
nifedipine caused a dose dependent decrease in APD75 illustrating its ef-
fect on Ca2+ channels [144], while the FDSS/μCELLwas used to monitor
changes in astemizole-induced calcium transients in Cor.4 U CMs in a
384-well format [187]. Using the FLIPR tetra in conjunction with a
Calcium 5 kit enabled the beat rate, peak shape and regularity to be
monitored in response to 131 compounds comprising cardiac glyco-
sides, anti-arrhythmics, α−/β-adrenoceptors, Ca2+ blockers and anti-
histamines [187].
However, ﬂuorescent dyes are inherently phototoxic, which can
cause temporal degradation of sample and signal quality over time,
thereby limiting recording times [185]. This can be overcome by intro-
ducing genetically encoded voltage indicators (GEVIs), such as ArcLight
GEVI, which has recently been used to image hiPSC-CM action poten-
tials during drug screening [186]. In this study, ArcLight allowed the ac-
curate prediction of arrhythmic effects, which was comparable to patch
clamp measurements [186]. Unlike VSDs, GEVIs also allow speciﬁc cell
populations to be targeted and provide homogenous signal intensities
independent of cell uptake [186]. Nevertheless, VSDs or GEVIs provide
surrogates of membrane potentials and tend to overestimate action po-
tential duration [185,188].
4.3.4. Contraction and force generation
Excitation–contraction coupling leads to force generation, which is
the ultimate goal of theworkingmyocardium. As such, variousmethods
have been developed to measure contractility of CMs, including atomic
force microscopy [103], ﬂexible cantilevers [189] strain gauges [190],
magnetic beads [191], optical edge detection [192], polyacrylamide
gels [193], muscular thin ﬁlms [194], carbon ﬁbre deﬂection [195],
microposts [196] and image based label-free method [197]. Eachmethod
prepares, measures and reports force in a different way (e.g. clamping,
bonding, poking), whichmakes cross-comparison of the values produced
rather challenging. Nevertheless, force generation has been measured
fromhPSC-CMs in presence or absence of pharmacology (Table 4). Twitch
forces for hPSCs-CM range from 2-260nN for single hPSC-CMs [123,196,
198] and 0.08–4.4 mN/mm2 for 3D hPSC-CM derived EHTs [199]. This is
relatively low compared with the microN range of single adult CM [124]
and 40-80mN/mm2 range of muscle human strips [200]. This reinforcesthe need to evaluate the effect on hPSC-CM contractility of the different
maturation strategies discussed above, including incorporation of non-
cardiomyocyte populations found in the heart (i.e. endothelial cells, ﬁbro-
blasts, smooth muscle cells).
Translating these approaches into medium- to high-throughput is
challenging and only a few examples exist. The use of impedance to re-
port on contractility is becoming popular even though this is a surrogate
measure and its accuracy needs to be established more thoroughly. The
premise is that as CMs contract and relax, nano-scale changes in mor-
phology andmembrane structure alter the level of impedance between
cell and underlying substrate. These characteristics are exploited by
electric cell-substrate impedance sensing platforms, which incorporate
gold-ﬁlm electrodes into the bottom of tissue-culture plates [201,202].
Rapid (12.9 ms update rate/plate) data acquisition frequencies [203]
allow the resolution of subtle changes in CMbeat proﬁling including ar-
rhythmic events and the continuous monitoring of cell index is useful
for cardiotoxicity proﬁling [204]. Of the impedance platforms, the
xCELLigence has been most widely used on hPSC-CMs. This showed
testing of a panel of 49 cardioactive compounds on hiPSC-CM had
sensitivity, speciﬁcity and accuracy of 90%, 74%, and 82%, respective-
ly, which compared favourably when compared to in vitro data for
dog (83%, 84% and 82%) and rat (77%, 74%, and 74%) CMs [205].
The CardioExcyte96 [206] is a newer platform that measures both
impedance and extracellular ﬁeld potentials, allowing study of
hPSC-CM beat rates, amplitudes and electrophysiology (Table 4).
Nonetheless, our own experiences are that improvements are need-
ed in the number of wells that lead to productive recordings (often
as low as 15%), as well as to signal recording and data analysis,
which are predominately handled as manually processes and limit
throughput.
It is probable that direct measurement of contractility in 3D EHTs
will provide a more accurate readout than the indirect method of
impedance. Multiplexing hPSC-CM EHTs in a 24-well format has
shown differences between the maximal twitch forces (0.22, 0.05, and
0.08mN) and sensitivity to external Ca2+ (EC50: 0.15, 0.39, and
1.05 mM Ca2+) of rat, mouse, and human EHTs. Evaluating the impact
of drug panels on contractility in hPSC-CMderived EHTs is now also un-
derway, which will provide an important resource to the pharmaceuti-
cal industry [135].
5. Conclusions & future challenges
Over the last 3–5 years, hPSC-CM technologies have transformed.
Challenges of hPSC culture have largely been overcome by the develop-
ment of deﬁned medium, while differentiation strategies to produce
CMs at scale are being reﬁned rapidly. New tools for producing
integration-free hiPSC and engineered Cas9/CRISPR cells mean that
the range of genotypes available is broader than ever. Isogenic pairs of
healthy and diseased hPSCs provide sets of cell lines in which only the
mutation differs in an otherwise identical genetic background. This will
offer unrivalled opportunities to examine impact of polymorphisms
identiﬁed from genome-wide association studies (GWAS). These ad-
vances have enticed interest from the pharmaceutical industry with the
promise of replacing suboptimal drug safety assessment platforms with
physiologically-relevant human cardiomyocytes. Indeed, there have
been spectacular successes with hPSC-CMs being used to reﬁne patient
treatment, assist in progressing drugs to Phase I clinical trial and
evaluate tens if not hundreds of drugs in medium content assays.
Such observations have prompted the CIPA initiative, which will
write a new chapter of safety assessment guidelines using hPSC-
CMs. The progression of hPSC-derived cardiac cells to the clinic is
also an important milestone.
Nevertheless, the excitement needs to be temperedwith the realisa-
tion that, relative to many in vitromodels, hPSC-CMs are expensive to
produce and beyond the tolerated ‘price point per well’ of most Pharma
screening budgets. Consistency of hPSC-CM production needs to be
Table 4
Phenotyping platforms for hPSC-CMs. Examples currently have medium-high content capacity or have future potential.
Platform hESC-CM hiPSC-CM Condition Mutation Purpose Assay Outcome Refs
High content imaging
Confocal microscope n/a 10 patients HCM βMHC:
Arg663His
Hypertrophy L-type Ca2+ block 100 nM verapamil ↓ hypertrophy [212]
ArrayScan VTi 2D
Confocal opera LX
H7, HUES7, SHEF3 CDI iCells
Axio Cor4U
ReproCardio2
Patient cells
Healthy &
LQTS2
KCNH2
c.G1681A
Hypertrophy Phenylephrine stress ↑ in 2D cell area of hESC-CMs but not hiPSC-CMs [74]
IC 100/200 H9 CDI iCells Healthy n/a Ca2+ & drug risk Fluo-4AM EC50 Verapamil, 0.26μM; BayK 8644, 11nM [213]
ImageXpress Micro n/a CDI iCells Healthy n/a Hypertrophy Endothelin-1 + BNP EC50 enthothelin-1, 11pM [161]
ImageXpress micro n/a CDI iCells Healthy n/a Toxicity/viability 384-well CalceinAM, Hoechst,
MitoTracker
Cardiotoxicity of a 131 modulators of Na+, K+, Ca2+ channels
& adreno-, dopamine, histamine receptors
[38]
“Pulse” all-in-one system n/a CDI iCells
Axio Cor4U
GCaMP-engineered
Healthy n/a Cardioactives on beating Video imaging of in 24-well
plates
Norepinephrine: rate↑; cisapride, E-4031: arrhythmia, APD↑;
sotalol, quinidine: APD↑; verapamil, nifedipine: APD↓ [214]
“OptoDyce” n/a ChR2-engineered Healthy n/a n/s 96-well all-optical pacing &
E-phys
Nifedipine: ↓APD, ↓CTD [215]
Mitochondrial function
ArrayScan vTi n/a CDI iCells Healthy n/a Mitochondrial membrane
potential
TMRM dye Chelerythrine: ↓TMRM signal
Doxorubicin: no change
[162]
Seahorse XF analyser hESC1 & hESC2 Healthy & PomD Pompe
Disease
GAA Bioenergetics Extracellular ﬂux Up to 2-fold increase in OCR & ECAR in PomD hiPSC-CMs [167]
Seahorse XF analyser n/a Healthy & JK#2, JK#11 ARVD PKP2 Bioenergetics Extracellular ﬂux Treatment with insulin, dex, IBMX, rosiglitazone,
indamethacin changes glycolysis & fatty acid oxidation
[216]
Seahorse XF analyser n/a Healthy & DMD Duchene DMD Bioenergetics Extracellular ﬂux No difference between healthy & DMD [166]
Seahorse XF analyser n/a hiPSC Healthy n/a Bioenergetics Extracellular ﬂux T3: ↑ basal & max respiration, non-mitochondrial OCR [109]
Seahorse XF analyser H7 & RUES2 n/a Healthy n/a Bioenergetics Extracellular ﬂux ↑Max respiration capacity [108]
Seahorse XF analyser n/a Healthy & T1DMiPSC Type 1
Diabetes
n/s Bioenergetics Extracellular ﬂux Diabetes: ↓ basal OCR and ECAR; +Glucose: ↑ECAR, no change
in OCR;
+2DG: ↓ECAR, no change in OCR
[168]
Seahorse XF analyser NKX2-5eGFP/w
engineered
n/a Healthy n/a Bioenergetics Extracellular ﬂux ↓Maximum respiration
↓ Basal ATP turnover
[208]
Seahorse XF analyser & plate
luminometer
n/a BTH-H, BTH-C, WT1,
WT2, WT3
Barth
Syndrome
TAZ Bioenergetics Extracellular ﬂux ↓ Respiration capacity in patient CMs [129]
ATP production Bioluminescent ATP ↓ ATP generation in patient CMs
Calcium imaging
ImageXpress Micro n/a CDI iCells Healthy n/a Beat rates Calcein AM IC50 epinephrine: 50nM
IC50: isoproterenol: 6nM
[163]
IonOptix n/a EHT Healthy n/a Ca2+ transients Fura-2 EC50 of 1.05mM Ca2+ in human EHTs [134]
FDSS/μCELL n/a Axio Cor4U Healthy n/a Calcium transients FLIPR Calcium 5 Ca2+ transients change with astemizole [187]
FLIPR Tetra 384 n/s n/s Healthy n/a Beat rate, peak shape and
regularity
FLIPR Calcium 5 131 compounds: cardiac glycosides, anti-arrhythmics,
α-/β-adrenoceptors, Ca2+ blockers, anti-histamines
[38]
Leica confocal n/a Healthy n/a Ca2+ proﬁle; toxicity Fluo-4AM Ca2+ perturbations: astemizoleN thioridazineN cisaprideN
ﬂecainideN valdecoxibN sotalolN nadolol
[217]
IonOptix & IonWizard n/a CDI iCells Healthy n/a Ca2+ transients Fluo-2 51 compounds: 70% speciﬁcity; 87% sensitivity; IC50 of 18 drug
panel
[39]
FLIPR Tetra FLIPR Calcium 5
Automated planar patch clamp for intracellular/whole-cell/patch recordings
PatchXpress 7000A n/a CDI iCells Healthy n/a INa, ICa, IKr Voltage clamp IC50: TTX, 0.64 μM; nifedipine, 38nM [24]
QPatch GE Cytiva CDI iCells Healthy n/a INa, ICa, IK; AP induction Voltage + current clamp IC50: TTX, 10.3μM; nifedipine, 95.3nM; APA: 80Mv; APD:
400ms
[176]
Patchliner n/a Axio Cor4U Healthy n/a INa, IK; AP induction Voltage + current clamp BayK 8644: ↑APD & APA; TTX: blocked AP induction [177]
CytoPatch™2 n/a Axio Cor4U Healthy n/a INa, IK; AP induction;
pharmacology
Voltage + current clamp Nifedipine: ↓APD90; cisapride: ↑APD90; TTX: ↓APD90 [178]
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Multi-electrode arrays for recordings of Extracellular Field Potentials (EFP)
MEA2100 n/a CDI iCells Healthy n/a Compounds on beat rate
and amplitude
6-well MEA TTX, ZD72 8: ↓BR; ISO: ↑BR + ↑BA; Ouabain ↑BA; Nifedipine:
↓BA + ↑B E4031/RO5657: arrhythmias suppressed by
nifedipine
[218]
MEA1060-Inv-BC n/a UTA.04602.WT Healthy n/a E4031 on EFP proﬁle 6-well MEA E4031 ↑F & ↓amplitude of Na peak [219]
MEA60 n/a CDI iCells Healthy n/a Compounds on FPD 6-well MEA IKr blocke ↑FPDC, arrhythmias; IKs blockers: ↑FPDC; ICa,L
blockers: PDC
[220]
Maestro GE cytiva n/a Healthy n/a Compounds on FPD 48-well MEA 21-drug p el: hERG blockers, ↑FPD; Na blockers, ↑FPD; Ca
blockers, PD; Ca activators, ↑FPD
[221]
Maestro n/a CDI iCells Healthy n/a Compounds on FPD 48-well MEA 15-drug p el: hERG blockers, ↑FPD; IKs blocker L768673, No
effect on D
[181]
Maestro n/a CDI iCells Healthy n/a Compounds on FPD 48-well MEA Verapami uabain: ↓FPD; ranolazine, amiodarone,
terfenadin , ﬂecainide, cisapride: ↑FPD
[180]
Impedance for quantiﬁcation of CM contractility
xCELLigence RTCA n/a CDI iCells Healthy n/a Compounds on beating 96-well assay beat rate &
amplitude
TTX, ZD72 8: ↓BR; ISO: ↑BR + ↑BA; Ouabain ↑BA; Nifedipine:
↓BA + ↑B E4031/RO5657: arrhythmias suppressed by
nifedipine
[218]
xCELLigence RTCA n/a CDI iCells Healthy n/a Compounds on beating 96-well assay beat rate &
amplitude
Amlodipi : ↑BR, ↓BA; Mibefradil: No effect; E4031: ↓BR,
arrhythm ; Zatebradine: ↓BR
[222]
xCELLigence RTCA n/a CDI iCells Healthy n/a Compounds on beating 96-well assay beat rate &
amplitude
Beat rate: 2.8±0.87bpm; crizotinib, sunitinib: ↓BR / beating
cessation
[223]
xCELLigence RTCA n/a CDI iCells Healthy n/a Compounds on beating 96-well assay beat rate &
amplitude
Dofetilide 4031: ↓BA, arrhythmias; HMR1556: no change;
TTX: ↓BR, BA; Verapamil: ↓BA, ↑BR
[224]
xCELLigence RTCA n/a CDI iCells Healthy n/a Compounds on beating 96-well assay beat rate &
amplitude
Detected 9 positive inotropes (78%); 20/21 negative
inotropes 5%); 14/19 negative controls had no effect
[205]
xCELLigence RTCA n/a CDI iCells Healthy n/a Cardiotoxicity 96-well assay beat rate &
amplitude
16/18 dru with known toxicities caused changes in beat
pattern
[225]
2D platforms for studying cardiac contractility
Atomic force microscopy H7 Stemcell technologies Healthy n/a Beat rate, contraction force AFM cantilever tip (single well) Beat rate: .80/s (single cell) or 1.72/s (aggregates); Force:
single cel 2.37 nN; norepinephrine from 0.18 nN to 0.48nN
for Ipsc-C s and 0.097nN to 0.37 nN for H7
[196]
Microposts n/a IMR-90 Healthy n/a Contraction, relaxation,
power
High-speed video microscopy
(single well)
Twitch ve cities 1.4-2.0 μm/s contraction; 1.2-1.6 μm/s
relaxation peak contraction: 29 fW; systolic forces: 15nN/cell
[198]
Impedance n/a CDI iCells Healthy n/a Beat rate and amplitude 96-well Impedance 49 positiv & negative inotropes for cardiac contractility:
change be rate
[205]
Displacement of ﬂuorescent
beads
n/s n/s Healthy n/a Contractility 6-well microscopy 0.26 mN/ 2 for iPSC-CMs and 0. 29 mN2 for hESCs [123]
3D platforms for studying cardiac contractility
Bioartiﬁcial cardiac tissue (BCT) n/a n/s Healthy n/a Contractility Bioreactor 4.4 mN/m 2 [199]
Fibrin based engineered human
tissues (EHTs)
hESC clone C25 Healthy n/a Contractility 24-well video-optical ISO: force (185%), contraction time ↓,relaxation time↓; ISO +
xiaﬂex: fo e↓, relaxation time↑; twitch force 0.08 mN/mm2
for Ipsc-C s
[134,226]
3D cardiac micro tissues (CMTs) hES2 CD34+ precursors for
iPSCs
Healthy and
Ad-PLB
n/a Contractility Optical (photometric camera)
up to 96 well
Twitch te ion for hvCMTs after Ad-PLB treatment↓ from 5.8
μN to 2.2 , ISO: 119% ↑ of force and twitch tension a 4.5 μN
[227]
Multi-parameter analysis
CellOPTIQ n/a CDI iCells Healthy n/a Action potential & T-rise Voltage sensitive dye
di-4-ANEPPS
E4031: ↓A D50, APD75 & APD90; Nifedipine: ↓ APD75;
Mexiletin Trise
[144]
CellOPTIQ n/a CDI iCells Healthy n/a Action potential Voltage sensitive dye
di-4-ANEPPS
bs906: no ffect on APD50 & APD90; ISO: ↑ APD50 & APD90
reversed th bs906
[228]
CardioExcyte96 GE Cytiva
Cellectis clusters
CDI iCells
Axio Cor4U
ReproCardio2
Healthy n/a Compounds on beat proﬁle
& EFP
CardioExcyte 96 combined
impedance & EFP
Nifedipin ↓Amplitude/FPD; E4031: ↓ amplitude, ↑FPD, EADs
and beati cessation; S-BayK8644: ↓ amplitude
[206]
HCM, hypertrophic cardiomyopathy; LQTS, long QT syndrome; n/a, not applicable; n/s, not speciﬁed; APD, action potential duration; CTD, calcium transient duration, OCR, oxygen nsumption rate; ECAR, extracellular acidiﬁcation rate; TMRM,
tetramethylrhodamine, methyl ester; T3, triiodothyronine; EHT, engineered heart tissue; APA, action potential amplitude; TTX, tetrodotoxin; FPD, ﬁeld potential duration; BR, beat ra ; ISO, isoprenaline; BA, beat amplitude; CDI, Cellular Dynamics
International; Axio, Axiogenesis.
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Fig. 4. Automated image analysis of hPSC-CMs. Panel (A) shows images captured on the Perkin Elmer Operetta confocal plate reader of hPSC-CMs stained with ofα-actinin (Ai). Analysis
using Harmony™ image software identiﬁes cellular nuclei and cytoplasmic regions (Aii), which is then texture-ﬁltered (Aiii) to allow recognition of subcellular structures (Aiv). In (B),
automated processing gives quantitative metrics in a high throughput manner that can be used for rapid phenotyping of hPSC-CMs.
1744 C. Denning et al. / Biochimica et Biophysica Acta 1863 (2016) 1728–1748improved during scale up and there is a need for better deﬁnition of CM
subtype following differentiation. In this regard, it is encouraging that
recent protocols have been developed to specify ventricular, atrial and
pacemaker cells from hPSCs, and it will now be important to see if
these methods can be reproduced in other laboratories. Maturation
of hPSC-CMs continues to be a considerable issue for the ﬁeld.
While individual biochemical and mechanical cues provide incre-
mental improvements in maturity, there has not yet been the leap
needed to produce the adult CM phenotype. Whether this will
ever be achieved is unknown but it might not be needed. Each im-
provement will extend the utility of hPSC-CMs further and they
are already proving their worth.
The glut of patient-derived or engineered hPSC lines poses a pheno-
typing bottleneck to understand the biology of the cardiomyocytes. In-
tegration of these cells into medium- to high-throughput platforms is
now playing catch-up and over the next 2–3 years it can be expected
that single, cost-effective platforms will become available for simulta-
neously reporting on electrophysiology, calcium and contractility in
the presence or absence of pathophysiological load to mimic the failing
heart. This will be amajor step towards changing the face of drug safety
screening and disease modelling.Conﬂict of interest
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